 
  
 
    
A Randomized Phase II Trial of Low Dose Aspirin versus Pla cebo in High-Risk Individuals 
with CT-Detected Subsolid Lung Nodules 
  
IEO Protocol #: IEO 833/13F (IEO 37) 
 EUDRACT Protocol #: 2013-004862-32  
 
    
PI: Bernardo Bonanni, MD 
 Division of Cancer Prevention and Genetics,  IEO    
 
Co-PI: Lorenzo Spaggiari, MD  Department of Oncology and Hemato -Oncology—DIPO, University of Milan 
 University of Milan 
Director Lung Cancer Program 
 IEO   Protocol version: #9  Date version: March 13, 2017 
 
Sponsor: European Institute of Oncology     Via Ripamonti, 435     20141 Milan (Italy)   
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –2– 
05/21/2013  COVER PAGE 
 
DCP Protocol #:  MDA2013-01-01 
MDACC Protocol#: 2013-0732 
EIO Protocol #: IEO 833/13F (IEO37)  
 
EUDRACT Protocol #: 2013-004862-32 
 
A Randomized Phase II Trial of Low Dose Aspirin versus Pla cebo in High-Risk Individuals 
with CT-Detected Subsolid Lung Nodules 
  
Consortium Name: University of Texas MD Anderson Early Phase Clinical Research 
Consortium  
Name of Consortium Principal Powel H. Brown, MD, PhD  
Investigator: Professor and Chair, Department of Clinical Cancer Prevention 
 University of Texas MD Anderson Cancer Center  
 1515 Holcombe Boulevard, Unit 1360 
Houston, TX 77030-4009 Telephone: (713) 792-4509 
Fax: (713) 794-4679 
phbrown@mdanderson.org  
 
MD Anderson Consortium Lana A. Vornik, MHA, MS  
Administrative Director: Administrative Director, Protocol Research  
 Department of Clinical Cancer Prevention 
 University of Texas MD Anderson Cancer Center  
 1515 Holcombe Boulevard, Unit 1360 
Houston, TX 77030-4009 Telephone: (713) 792-9594 Fax: (713) 745-4230 
lavornik@mdanderson.org  
 
 
Organization Name:   European Institute of Oncology  
Protocol Principal Investigator:  Bernardo Bonanni, MD  
  Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0257489863 
  Fax+39-0294379225 
  E-mail address: bernardo.bonanni@ieo.it 
 
Co-Principal Investigator:   Lorenzo Spaggiari, MD  
     Department of Oncology and Hemato-Oncology—DIPO, 
     University of Milan  
  Director Lung Cancer Program 
  European Institute of Oncology 
  Via Ripamonti, 435 
  20141 Milan, Italy 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –3– 
05/21/2013    Telephone: +39-0257489665 
  Fax: +39-0294379218 
   E-mail address: lorenzo.spaggiari@ieo.it 
 
 
Organization      Massimiliano Cazzaniga, MD 
Investigator:  Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0294379656 
  Fax+39-0294379225 
  E-mail address: massimiliano.cazzaniga@ieo.it 
 
Organization      Matteo Lazzeroni, MD 
Investigator:  Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0294379652 
  Fax+39-0294379225 
  E-mail address: matteo.lazzeroni@ieo.it  
 
Organization     Davide Serrano, MD 
Investigator:  Division of Cancer Prevention and Genetics 
  European Institute of Oncology  
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0294379653 
  Fax+39-0294379225 
  E-mail address: davide.serrano@ieo.it 
 Organization     Clara Varricchio, MD 
Investigator:  Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0257489863 
  Fax+39-0257489809 
  E-mail address: clara.varricchio@ieo.it  
 
Organization    Massimo Bellomi, MD 
Radiologist:   Division of Radiology, European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0257489042 
  Fax+39-0257489040 
  E-mail address: massimo.bellomi@ieo.it  
 
Organization    Cristiano Rampinelli, MD 
Radiologist:   Division of Radiology, European Institute of Oncology 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –4– 
05/21/2013   Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0257489042 
  Fax+39-0257489040 
  E-mail address: cristiano.rampinelli@ieo.it 
 
Organization      Pierpaolo di Fiore, PhD 
Lab Investigators   Molecular Medicine for Care Program 
     Department of Experimental Oncology       
     Fabrizio Bianchi, PhD   Molecular Medicine for Care Program 
  Department of Experimental Oncology 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0294375173 
  Fax+39-0294379305 
  E-mail address: Fabrizio.bianchi@ieo.eu  
 
Organization      Harriet Johansson, PhD 
Lab Investigator:  Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0294379654 
  Fax+39-0294379225 
  E-mail address: harriet.johansson@ieo.it 
 Organization      Claudia Passoni, RN 
Research Nurse:   Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
  Telephone:+39-0257489861 
  Fax+39-0294379225 
  E-mail address: claudia.passoni@ieo.it 
 Organization      Aliana Guerrieri-Gonzaga, MSc 
Study Coordinator:   Division of Cancer Prevention and Genetics 
  European Institute of Oncology 
 Via Ripamonti, 435 
 20141, Milan, Italy 
 Telephone: +39-0257489893  Fax +39-0294379225  E-mail address: aliana.guerrieri-gonzaga@ieo.it  
 
Organization      Serena Mora, MA 
Site Data Manager:  Division of Cancer Prevention and Genetics   European Institute of Oncology 
 Via Ripamonti, 435 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –5– 
05/21/2013   20141, Milan, Italy 
 Telephone: +39-0294379657  Fax +39-0294379225 
     E-mail address: serena.mora @ieo.it  
 
Organization   Davide Radice, MSc  
Site statistician:   Division of Epidemiology and Biostatistics,  
 Via Ripamonti, 435 
 20141, Milan, Italy  Telephone: ++39-0257489821 
 Fax: ++39-0257489813  E-mail address: davide.radice@ieo.it 
 Organization   Patrick Maisonneuve, Ing.  
Site senior statistician:   Division of Epidemiology and Biostatistics,  
 Via Ripamonti, 435 
 20141, Milan, Italy  Telephone: ++39-0257489820  Fax: ++39-0257489813 
 E-mail address: patr ick.maisonneuve@ieo.it 
 
Organization:    University of Texas MD Anderson Cancer Center 
Site Principal Investigator:  Therese Bevers, MD  
  Professor, Department of Clinical Cancer Prevention 
 1515 Holcombe Boulevard, Unit 1360 Houston, TX 77030-4009 
Telephone: (713) 745-8048 Fax: (713) 792-0628 
tbevers@mdanderson.org  
 
Organization:    University of Texas MD Anderson Cancer Center Site Principal Investigator:  Myrna Godoy, MD 
Associate Professor, Diagnostic Radiology - Thoracic Imaging  T. Boone Pickens Academic Towe (FCT15.5046) 1515 Holcombe Blvd., Unit 1478 Houston, TX 77030  
Telephone: (713) 792-6001 
mgodoy@mdanderson.org  
  Organization:    University of Texas MD Anderson Cancer Center 
Site Principal Investigator:  Jeremy J Erasmus, MD 
Professor, Diagnostic Radiology - Thoracic Imaging  T. Boone Pickens Academic Towe (FCT15.5080) 1515 Holcombe Blvd., Unit 1478 Houston, TX 77030  Telephone:  (713) 792-5878  
jerasmus@mdanderson.org   
 
 
Organization:   University of Texas MD Anderson Cancer Center  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –6– 
05/21/2013  Lead Statistician:   J. Jack Lee, Ph.D.  
  1515 Holcombe Boulevard, Unit 447 
Houston, TX 77230 
  Telephone: (713) 794-4158 
  Fax: (713) 563-4242 
 jjlee@mdanderson.org   
  
Sponsor :   European Institute of Oncology 
    Via Ripamonti, 435 
    20141 Milan, Italy 
 
Financial support:  NCI/Division of Cancer Prevention 
    9609 Medical Center Drive, Rm 5E-536     Rockville, MD  20850  
    (240) 276-7050 
 
Agent(s)/Supplier : Aspirin  /Bayer Europe   
 
NCI Contract # HHSN261201200034I  
 
Protocol Version Date:   March 13, 2017 
 
Protocol Revision or  Version 14  
Amendment #   Amendment7  
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –7– 
05/21/2013  SCHEMA 
 
 
A Randomized Phase II Trial of Low Dose Aspirin v ersus Placebo in High-Risk Individuals with 
CT-Detected Subsolid Lung Nodules 
 
Asymptomatic volunteers (128) current/former smokers (>20 pack-years), age >50 years, with persistent 
subsolid lung nodules confirmed by CT scan 
 
CT scan and phone contact (days -61 - 0) 
CT scan lung lesion measurement for nodule eligibility and phone contact for additional eligibility 
assessment 
 
Baseline visit (days -61 - 0) 
Informed consent, medical history, physical exam, tobacco assessment, concomitant medication, baseline 
symptoms, clinical lab tests (pregnancy test, if applicable), blood and urine collection 
 
Randomization (Month 0) 
Confirm eligibility, randomize (stratify by screeni ng vs non screening CT scan, gender, smoking status 
(current vs former), nodule characteristics (non solid vs partially solid) 
 
Intervention 
Aspirin 100 mg/day or placebo qd for 12 months 
 
Telephone contact (Month 1 + 1 W) 
Toxicity assessment, concomitant medications, review of self reported compliance 
 
Telephone contact (Month 3 + 2 W) 
Toxicity assessment, concomitant medications, review of self reported compliance 
 
Clinic Visit (Month 6 + 2 W) 
Physical exam, toxicity assessment, tobacco assessmen t, concomitant medication, clinical lab tests 
(pregnancy test, if applicable), blood and ur ine collection, compliance/review pill diary 
 
Telephone contact (Month 9 + 2 W) 
Toxicity assessment, concomitant medications, review of self reported compliance 
 
Clinic Visit (Month 12 + 2 W) 
Physical exam, toxicity assessment, tobacco assessmen t, concomitant medication, clinical lab tests 
(pregnancy test, if applicable), blood and urine collection, drug compliance/review pill diary, CT scan-
detected lesion measurement 
 
Telephone contact (Month 13 + 1 W) 
Toxicity assessment, concomitant medications 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –8– 
05/21/2013  TABLE OF CONTENTS 
COVER PAGE..................................................................................................................... ......................... 2  
SCHEMA ........................................................................................................................ .............................. 7 
TABLE OF CONTENTS ............................................................................................................. ................. 8  
1.  OBJECTIVES .................................................................................................................... ............ 10  
1.1 Primary Obj ectives ............................................................................................................ ............................ 10  
1.2 Secondary Ob jectiv es .......................................................................................................... .......................... 10  
2.  BACKGROUND .................................................................................................................... ....... 10 
2.1 Lung cancer ................................................................................................................... ................................ 10  
2.2 Aspirin ....................................................................................................................... .................................... 10  
2.3 Rationa le ..................................................................................................................... .................................. 11  
3.  SUMMARY OF STUDY PLAN ................................................................................................... 14  
4.  PARTICIPANT SELECTION ....................................................................................................... 15  
4.1 Inclusion Criteri a ............................................................................................................ ............................... 15  
4.2 Exclusion Cr iteria ............................................................................................................ .............................. 16  
4.3 Inclusion of Wome n and Mino rities ............................................................................................. ................. 16  
4.4 Recruitment and Retention Plan ................................................................................................ .................... 17  
5.  AGENT ADMINISTRATION ...................................................................................................... 18  
5.1 Dose Regimen and Dose Groups .................................................................................................. ................. 18  
5.2 Aspirin Administ ration ................................................................................................................ .................. 18  
5.3 Run-in Procedures ............................................................................................................. ............................ 19  
5.4 Contraindications ............................................................................................................. ............................. 19  
5.5 Concomitant Me dications ....................................................................................................... ....................... 19  
5.6 Dose Modi ficatio n ............................................................................................................. ............................ 19  
5.7 Adherence/Co mpliance .......................................................................................................... ....................... 21  
6.  PHARMACEUTICAL INFORMATION ...................................................................................... 22  
6.1 Study Agent (IND #, IND Sponsor) .............................................................................................. ................ 22  
6.2 Reported Adverse Events  and Poten tial Ri sks .............................................................................................. 22  
6.3  Availability .................................................................................................................................................... 23  
6.4 Agent Distributio n ............................................................................................................ ............................. 23  
6.6 Packaging an d Labe ling ................................................................................................................................ 24  
6.8 Registration/Ra ndomization .................................................................................................... ...................... 24  
6.9 Blinding and Unblinding Me thods ............................................................................................... ................. 25  
6.10 Agent Destructi on/Disposal .......................................................................................................................... 26  
7.  CLINICAL EVALUATIONS AND PROCEDURES ................................................................... 26  
7.1 Schedule of Events ............................................................................................................ ............................ 26  
7.2 Prestudy Evaluation/Base line Visit/Reg istration ............................................................................... ............ 28 
7.3 Evaluation During St udy Interv ention .......................................................................................... ................. 29  
7.4 Evaluation at Completion of Study In tervention ................................................................................ ........... 29 
7.6 Methods for Clini cal Proce dures ............................................................................................... .................... 29  
8.   CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION ........................................... 31  
8.1 Primary En dpoint .............................................................................................................. ............................ 31  
8.2 Secondary Endpoints ........................................................................................................... .......................... 31  
8.3 Off-Agent Criteri a ............................................................................................................ ............................. 33  
8.4 Off-Study Criteria ............................................................................................................ ............................. 33  
8.5 Study Term inatio n ............................................................................................................. ............................ 33  
9.  CORRELATIVE/SPECIAL STUDIES ......................................................................................... 33  
9.1 Rationale for Metho dology Selection ............................................................................................................ 33  
9.2 Comparable Methods ............................................................................................................ ........................ 35  
10.  SPECIMEN MANAGEMENT ...................................................................................................... 35  
10.1 Laborato ries .................................................................................................................. ................................. 35  
10.2 Collection and Hand ling Procedures ............................................................................................ ................. 36  
10.3 Shipping Inst ructio ns ......................................................................................................... ............................ 37  
10.4 Tissue Ba nking ................................................................................................................ .............................. 37  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –9– 
05/21/2013  11.  REPORTING ADVERSE EVENTS/adverse Drug reactions........................................................ 37  
11.1 Adverse Events ................................................................................................................ .............................. 38  
11.2 Serious Adverse Events ........................................................................................................ ......................... 39  
12.  STUDY MONITORING ............................................................................................................... 41  
12.1 Data Management ............................................................................................................... .......................... 41  
12.2 Case Report  Forms ........................................................................................................................................ 41  
12.3 Source Documents .............................................................................................................. ........................... 42  
12.4 Data and Safety M onitoring Plan ............................................................................................... ................... 42  
12.5 Sponsor or FD A Monito ring ......................................................................................................................... 42  
12.6 Record Re tentio n .............................................................................................................. ............................. 43  
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA) ............ 43  
13.  STATISTICAL CONSIDERATIONS ........................................................................................... 44  
13.1 Study Design/De scription ...................................................................................................... ........................ 44  
13.2 Randomization/St ratifica tion .................................................................................................. ....................... 45  
13.3 Accrual and Feasib ility ....................................................................................................... ........................... 45  
13.4 Primary Objective, Endpoint(s), Analys is Plan ................................................................................. ............ 45 
13.5 Secondary Objectives, Endpoi nts, Analys is Plans ............................................................................... ......... 45 
13.6 Reporting and Exclusions ...................................................................................................... ........................ 45  
13.7 Evaluation of Toxic ity ........................................................................................................ ........................... 46  
13.8 Evaluation of Response ................................................................................................................................. 46  
13.9 Interim Analysis  ............................................................................................................................................ 46  
13.10 Ancillary Studies ............................................................................................................. .............................. 46  
14.  ETHICAL AND REGULATORY CONSIDERATIONS ............................................................. 46 
14.1 Form FDA 1572 ................................................................................................................. ........................... 46  
14.2 Other Required Documents ...................................................................................................... ..................... 46  
14.3 Institutional Review  Board Approval ........................................................................................... ................. 47  
14.4 Informed Consen t .............................................................................................................. ............................ 47  
14.5 Submission of Regul atory Documents ............................................................................................ .............. 47  
14.6 Other ......................................................................................................................... ..................................... 48  
15.  FINANCING, EXPENSES, AND/OR INSURANCE ................................................................... 48  
REFERENCES .................................................................................................................... ....................... 49  
APPENDIX A .................................................................................................................... ......................... 62  
Appendix B Clinic diary/calendar .............................................................................................. ................. 63  
APPENDIX C .................................................................................................................... ......................... 65  
APPENDIX D .................................................................................................................... ......................... 66  
APPENDIX A: Performance Status Criteria  ...................................................................................... ...........  
APPENDIX B:  Clinic diary/calendar ............................................................................................ ............ 60 
APPENDIX C:  COSMOS Trial Algorithm ........................................................................................... .... 62 
APPENDIX D: Smoking status definition ......................................................................................... ......... 63 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –10– 
05/21/2013  1. OBJECTIVES 
 
1.1 Primary Objectives  – The primary objective is the evaluation of the effect of Aspirin as a 
chemopreventive agent for lung cancer. Particularly, the efficacy of Aspirin in reduction of size and 
number of CT-detected lung subsolid nodules will be  evaluated in high-risk asymptomatic subjects 
currently undergoing CT screening programs at the European Institute of Oncology (EIO) and at MD 
Anderson Cancer Center (MDACC).  
In addition, we will include subjects undergoing CT  outside the context of a screening program with a 
subsolid nodule confirmed by pulmonary CT scan (qualifying scan).  The efficacy will be evaluated in a person-specific analysis .  
 
1.2 Secondary Objectives – Secondary objective of the study will be the modulation of biological 
markers after treatment and the correlation of these fi ndings with modification of lung nodules diameters. 
In particular we will evaluate the effect of Aspi rin on a signature of serum microRNA correlated to 
subsolid nodules. Other secondary endpoints will be  the per-lesion analysis including the evaluation of 
lung nodule density before and after treatment, the number and size of non target lesions including solid 
nodules and evaluation of response according to modi fied RECIST criteria. Additional biomarkers will 
include the modulation of ultrasensitive circulating hs -CRP, the evaluation of urinary cotinine as marker 
of tobacco exposure and investigation of the potential effect of aspirin according to its concentration, the 
measurement of urinary prostaglandin metabolit es (PGEM) and leukotriene (LTE4), both normalized 
normalized to urinary creatinine concentration. Seru m concentration of thromboxane B2 (TXB2) will be 
determined as a measure of compliance. We will also evaluate the tolerability of Aspirin at dose of 100 
mg/day . 
 
 
2. BACKGROUND 
 
2.1 Lung cancer 
 
Lung cancer is one of the most common cancers in humans and the annual incidence continues to grow. 
The burden caused by lung cancer is enormous worldw ide and largely due to tobacco use. In Western 
countries smoke cessation campaigns and stricter regulati ons are beginning to multiply. This strategy will 
surely achieve good results in the future. However, there are still age and gender groups (the younger and women) who are at present more reluctant to avoid smoking, while the smoking epidemic is hitting the 
underdeveloped countries more and more alarmingl y. In the meanwhile, new screening modalities are 
under evaluation: the most promising is currently spiral low-dose CT scan (ld-CT). 
 
2.2 Aspirin 
 
Aspirin, the first non steroidal anti-inflammatory  drug (NSAID) identified, may have anti-cancer 
properties, especially for diseases whose etiology imp licates the role of chronic inflammation, such as 
colorectal and lung cancer. The an ti-inflammatory effect of NSAIDs operates through inhibition of 
prostaglandins via suppression of cyclooxygenase-1 (COX-1) and COX-2. The most convincing evidence 
of this effect is derived from several recently p ublished meta-analyses of aspirin in the prevention of 
cardiovascular events which showed that daily aspirin  reduced the incidence of colorectal cancer and 
several other cancers and reduced metastases1-3. In 2011, Rothwell et al.4 pooled data from 8 double-blind 
randomized controlled trials of daily aspirin and anal yzed the effect of aspirin on cancer mortality as 
secondary endpoints. The 20-year risk of death due to all cancers was consistently lower in the aspirin 
groups than in the control groups and the benefit increased with duration of treatment. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –11– 
05/21/2013  Lung cancer-speci ﬁc mortality rates were reduced by 29% (95%  CI, 11-42) in the aspirin group in the 20-
year period after the trial commenced4. No trend with dose (above 75 mg/day) was observed, but the 
effect on all cancers was more evident in adeno carcinomas and was present in both smokers and 
nonsmokers4. Several further observational studies have been  published. In a prospective cohort study, 
total NSAID use was associated with a small reducti on in risk of lung cancer, which was strongest for 
adenocarcinoma in men, and in long-term former smokers5. A suggestion of a protective effect of low-
dose aspirin was seen in the Women’s Health Study6. A hospital-base case-control study found that lung 
cancer risk was significantly lower for aspirin users co mpared to non-users and prolonged duration of use 
was associated with reduced lung cancer risk. Risk re ductions were observed in both sexes, but significant 
dose-response relationship were onl y seen among male participants7. 
Controversy remains regarding the most appropriate long-term daily dose of aspirin in the prevention 
setting. The mechanisms by which asp irin reduces the risk of cancer are not clear. COX-2 is thought to be 
the isoform most commonly implicated in carcinogen esis, but at the low doses (80-325 mg), aspirin has 
little activity against this isoform8. Aspirin is, in fact, 170 fold less effective at inhibiting COX-2 than 
COX-19. Nonetheless, aspirin may suppress the expression of COX-210, and it may also have 
antineoplastic effects that are unrelated to cyclooxygenase11,12. Since the 81-mg dose and the 325-mg dose 
appear to suppress colorectal prostaglandin levels to a similar extent13-15, we could postulate that the two 
doses may have equivalent potency through COX-relate d mechanisms. The major risk of aspirin, as with 
other NSAIDs, is the risk of bleeding. Although the an tiplatelet effects of aspirin likely contribute to an 
increase in the risk of bleeding, as highlighted by an increased risk of hemorrhagic stroke of 0.2 events 
per 1000 patient-years16, the majority of the increased bleeding ha s a gastrointestinal tract etiology. The 
influence of aspirin on gastric prostaglandin levels is dosage-dependent, with almost 50% inhibition at 
just 30 mg/d, but maximal inhibitio n requires approximately 1300 mg/d17. Consistent with these data, all 
conventional dosages of aspirin are associated with an increased bleeding risk. In a clinical trial in which 
1,121 patients with a recent history of histologi cally documented adenomas were randomly assigned to 
receive placebo (372 patients), 81 mg of aspirin (377 pa tients), or 325 mg of aspirin (372 patients) daily, 
the risk of bleeding was not a substantial problem and the risk of deat h and serious bleeding were similar 
among the groups18. In a case-control study of patients admitted with gastrointestinal bleeding, the odds 
ratio (OR) for admission with a bleeding ulcer was increased among aspirin users regardless of dosage19. 
Treatment with a 75-mg/d do sage of aspirin was associated with an  odds ratio of 2.3 for a bleeding ulcer 
(95% CI, 1.2-4.4), whereas 300 mg/d increased the OR to 3.9 (95% CI, 2.5-6.3).   
 
2.3 Rationale 
 
With the evolution of helical CT technology, CT screening for early detection of lung cancers is under 
evaluation in high risk individuals (former a nd current heavy smokers) with encouraging results20-22. At 
the EIO, a single center screening trial recruited 5, 202 high-risk volunteers (both current or former 
smokers) to undergo an annual multidetector low dose CT (ld-CT) for 5 or more years, beginning in 2004
21,23. The screening ld-CT, a non invasive test with low radiation exposure and no contrast medium, 
affords the opportunity to serially examine the peripher al lung for the first time, albeit with the limitation 
that small lesions cannot be biopsied an d thus their identity remains unknown.  
In September 2012, a new multicenter screening program has been launched at the EIO (Cosmos 2) with 
the aim of enrolling 10,000 high-risk individuals in 6 cen ters in Italy in a one-year period, with the goal of 
recruiting 5000 at the EIO. The Cosmos protocol re quires once yearly low-dose CT for 5 years. One of 
the main objective of the study is the validation of a serum signature of 34 circulating microRNA able to 
predict with high sensitivity the presence of an asympto matic lung cancer and to validate the Cosmos risk 
model24 on an independent cohort of high risk indivi duals to better select the target population for 
screening and the optimal screening interval. The population enrolled in the Cosmos 2 will represent the major source of potentially eligible subjects for the chemoprevention study. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –12– 
05/21/2013  In the meantime, two other screening programs are still ongoing at the EIO with annual ld-CT scans 
(Cosmos 1 and a pilot study) and they represent an  additional source of potential participants. 
Unfortunately, the high rate of benign nodules and i ssues of making a differential diagnosis are critical 
factors that currently hamper introduction of larg e-scale screening programs. Small pulmonary nodules 
are, in fact, a frequent finding in the subjects subm itted to ld-CT for early detection of lung cancer and 
have no clinical implications. Our data have demonstrated an incide nce of undetermined lung nodules in 
more than 50% of high risk individuals21. The nature of these nodules remained uncertain but it is 
reasonable that some of them could represent precancer ous lesions. In particular, literature suggests that 
ground glass opacities (GGO), as compared with solid nodules, can represent either localized 
bronchioloalveolar carcinoma without foci of active fibroblastic proliferation or atypical adenomatous 
hyperplasia20 which is a known putative adenocarcinoma precursor lesion25. The possibility to measure 
the nodule density in GGO lesions is an additi onal tool to monitor these preneoplastic lesions26. 
The actual identity of ld-CT detected GGO cannot be as certained without histologic analysis, but this is 
the category of nodule that is most likely to represent atypical alveolar hyperplasia, the putative precursor 
of pulmonary adenocarcinoma27. Kim et al. reported that of 53 persistent GGO in 49 patients who 
underwent resection, 68% proved to be bronchoalveolar carcinoma, 7. 5% were adenocarcinoma with 
predominant brochoalveolar components, 6% were at ypical adenomatous hyperplasia, and 19% were 
nonspecific fibrosis or organizing pneumonia28. Similarly, Ohtsuka et al. reported that of 26 patients who 
underwent resection, bronchoalveolar carcinoma w as diagnosed in 10 patients (38%), atypical 
adenomatous hyperplasia was diagnosed in 15 patients (58%), and focal scar was seen in 1 patient (4%)29. 
Although criteria such as size, the presence of air bronchograms, and nodule sphericity on CT scan have 
been used to differentiate carcinomas from atypical alveolar hyperplasia, histological analysis remains the 
gold standard for definitive categorization of nodul es and there continues to be debate regarding the 
overlap between small bronchoalveolar carcinomas and atypical alveolar hyperplasia30,31. Since resected 
nodules represent lesions that are suspicious enough to me rit surgery, it is possible and even likely that 
the smaller nodules identified in the context of our  ld-CT screening study represent less advanced 
neoplasia than described in the above cited studies as well as non-neoplastic etiologies.  In 2010 we published the results of the Budesoni de trial (MDA05-5-01), a randomized phase IIb study 
that evaluated the role of inhaled Budesonide in the shrinkage of CT detected undetermined lung nodules. 
The study showed an effect of the treatment onl y on non solid nodules and a trend in partially solid 
nodules
32. A 5-year follow up of the nodules with annual low dose CTs showed that the effect of 
treatment was maintained years after treatment a nd was significant for non solid and partially solid 
nodules (unpublished data). Specifically, after 60 months  the mean reduction of maximum diameter in the 
treated arm were 2.65 mm and 0.69 mm in the non- solid and partially solid lesions, respectively. 
 
We concluded that screen-detected non solid and partially solid nodules represent a good target to test 
chemopreventive agents and that the role of Budesonide deserves further investigation. 
 The University of Texas MD Anderson Cancer Cent er launched its Lung Cancer Screening Program in 
2011. To date, nearly 800 patients have been screen ed averaging approximately 20-30 screened patients 
per month. An additional resource for screening CTs is the active protocol entitled “ Biospecimen Banking 
and Biomarker Validation for Lung Cancer Early Detect ion in Cohort Receiving Low Dose Helical Computed 
Tomography Screening ” which has 194 patients currently enrolled. Although literature indicates the 
frequency of eligible lesions is approximately 30%, MDACC’s experience is slightly less at 10% (2-3 
patients per month) identified by low dose screening CT  scan. From this population, it is anticipated the 
Lung Cancer Screening program may enroll less than 1 e ligible patient per month after evaluation of other 
eligibility criteria. However, with the inclusion of lesions identified by diagnostic CT scan, MDACC’s 
large cancer survivor population offers a larger pool of potentially eligible patients undergoing CTs for 
surveillance. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –13– 
05/21/2013   
Based on the recent knowledge on the chemopreventive effect of Aspirin on lung cancer, we intend to evaluate the effect of low dose Aspirin (100 mg/day) on non solid and partially solid nodules identified in 
high risk volunteers submitted to annual low dose CT s among the ongoing screening programs at EIO and 
MDACC.   
In addition, we will include subjects undergoing CT  outside the context of a screening program with a 
subsolid nodule confirmed by pulmonary CT scan.  
 
Rationale for Biomarkers selection 
microRNA: Modulation of biological markers after treatment and the correlation of these findings with 
modification of lung nodules diameters will be investigated as secondary e ndpoints. In particular, we have 
recently identified serum circulating microRNA (miRNA)  able to accurately predict the presence of lung 
cancer during early stages disease33. The test was accurate enough to cap ture the onset of the disease in 
patients of whom serum samples were available before and after diagnosis of lung cancer by ld-CT. The 
same signature was also able to identify the pr emalignant GGO lesions among Cosmos 1 participants 
(unpublished data). In brief, we  screened a group of 27 individuals  with GGO lung nodules and applied 
the miRNA test. Twenty-four out of 27 were positiv es to the test (~89%). Furthermore, the average 
miRNA-test risk score of the GGO group was 12.5 wh ile the average score of two other groups of 
individuals with solid nodules (N=25), or without nodules (N=25), were -2.2 and -4.4 respectively (p 
<0.0001; Student’s t-test). This confirmed the validity  of the miRNA-test to pr edict the presence of GGO 
lesions as well as early stages lung cancer, and sugg est that active or passive release in the blood of 
specific miRNA species is already pr esent in lung premalignant lesions. 
The advantages of such a test compared to ld-C T are the potential for an easy applicability on a 
population-wide scale, the high potential for implementation of screening on a nation-wide scale, the absence of risks related to ionizing radiations, and the reduced costs As regards the technical aspects we have developed a fully automatized procedure based on low-density 
qRT-PCR array that allows the screening of expression of ~800 different miRNA species and using less 
than 300 l of serum. This will give us the opportunity to test every known miRNA present in the serum 
and to perform an accurate analysis of their quantities.  
We intend to apply the very same technology to identify  serum miRNAs predictive of the effect of aspirin 
treatment in patients with GGO lung nodules. 
 
C-reactive Protein: Inflammation has been hypothesi zed to increase the risk of cancer
34 although data 
from epidemiologic study are sparse. Many inflammatory conditions are well-known cancer precursors 
(Barrett’s esophagus, chronic gastritis , hepatitis, pancreatitis, and ulcerative colitis). So, early correction 
of inflammatory conditions by chemoprevention may be theoretically very useful. C-reactive protein 
(CRP), a member of the pentraxin family of prot eins involved with pattern recognition in innate 
immunity, is the principal downstream mediator of th e acute-phase response and is primarily derived via 
the interleukin 6-dependent hepatic biosynthesis35. Moreover, ultrasensitive CRP (hs-CRP) is an known 
index of subclinical systemic inflammation associated  with increased risk for cardiovascular events and 
diabetes. Elevated levels of hs-CRP have been linked to colon cancer development and a recent meta-
analysis36 including 1,918 lung cancer cases points to its implication also with lung cancer risk. 
Given our previous experience in measuring hs- CRP in subjects at higher risk for breast cancer37, we are 
interested in investigating change in hs-CRP also in subjects at higher risk of lung cancer. 
 
Cotinine: Measurement of cotinine, the nicotine meta bolite, provides an accurate estimate of recent 
tobacco smoke exposure and are able to account for i ndividual differences in smoking practices, such as 
depth of inhalation and how mu ch each cigarette is smoked38,39.	
 Prostaglandin (PGEM):  Prostaglandin synthesis is driven by th e two COX. Prostaglandin E2 is the most 
abundant prostanoid in the human body and it has been implicated in various tumorigenic processes and 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –14– 
05/21/2013  induces proliferation by activating at least two si gnalling pathways: Ras–Erk and glycogen synthase 
kinase-3β (GSK3β)–β-catenin in colon and lung cancer cells40. Circulating prostaglandin E2 is rapidly 
cleared by a single passage through the lungs and meas urement of the metabolites is necessary to provide 
a reliable estimate for its actual production. 
 
Leukotriene E4 (LTE4): Leukotriene E4 is an urinary metabolite indicating activation of the 
lipoxygenase pathway41. To perform urine analysis for LTE4, we will show relationship between acetyl-
salicylic acid (ASA) and the LTE4  shunt in healthy smokers. 
 
Thromboxane B2 (TXB2):  Thromboxane B2 is a biologically inactive metabolite of Thromboxane A2, 
an arachidionate metabolite with potent platelet aggregation activity and prothrombotic properties, that is 
rapidly hydrolyzed to TXB2. TXB2 is thus a su itable markers for monitoring platelet function and 
assessment of aspirin compliance. 
 
 
3. SUMMARY OF STUDY PLAN 
 
We will conduct a double-blind placebo-controlled ph ase IIb study in which participants will be 
randomized to receive either Aspirin (100 mg/day) or placebo for 12 months. 
 A total of 128 subjects will be accrued (randomized to  drug or placebo); 64 per arm in a 3.5 year time 
period.  
Participants will be men and women, current or former smokers, with unde termined subsolid lung 
nodules detected at low dose screening CT scan (without constrast medium) running at the EIO and 
MDACC. In addition, we will include subjects undergoing CT outside the context of a screening program, providing a subsolid nodule confirmation by a CT scan. Participants will be given 100 mg Aspirin daily or placebo for 12 months.  
 
The primary endpoint will be the shrinkage of GGO and partially solid lung nodules after one-year 
treatment per-subject analysis.   Secondary endpoints will be the modulation of biologi cal markers after treatment and the correlation of 
these findings with modification of lung nodules diameter s. In particular we will evaluate the effect of 
Aspirin on a signature of serum miR NA correlated to subsolid nodules. Other secondary endpoints will be 
the per-lesion analysis including the evaluation of lung  nodule density before and after treatment and the 
number and size of non target lesions. Additional biom arkers will include the modulation of hs-CRP, the 
evaluation of urinary cotinine as marker of tobacco exposure and investigation of the potential effect of 
aspirin according to its concentrati on, the measurement of urinary pr ostaglandin metabolites (PGEM) and 
urine leukotriene E4 (LTE4) both normalized to urinar y creatinine concentration. Serum concentration of 
thromboxane B2 (TXB2) will be determined as a measure of compliance. We will also evaluate the tolerability of Aspirin at dose of 100 mg/day.  Complete physical exam and safety lab tests will be pe rformed at 0, 6 and 12 months. Phone contact will 
occur at month 1, 3, 9 and 13 (i.e, one month after treatment completion).  
 
Biomarkers: blood and urine will be collected at 0, 6 and 12 months 
 Lung lesions will be measured with a CT scan at 0 and 12 months. Both standard dose and low dose CT 
scans are allowed provided that the same procedure is used at both time points. 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –15– 
05/21/2013  Duration of study will be five years: 3.5 years of accrual, one year of treatment and 0.5 year for 
biomarkers measurement.  
 
4. PARTICIPANT SELECTION 
 
4.1 Inclusion Criteria 
 
4.1.1 Asymptomatic current or former smokers (having stopped within the last 20 years). See Appendix 
D 
 
4.1.2 Age > 50 years (risk of lung cancer in subjects under 50 is low thus screening is not indicated by 
actual international guidelines) . 
 4.1.3  Smoking history > 20 pack/years; subjects must be included in an ongoing annual screening with 
low dose CT scan or 
 
must have two consecutive CT outside the context of a screening program confirming subsolid nodules as per inclusion criteria number 4.1.4. 
 
4.1.4 Subjects must have subsolid (non solid or pa rtially solid) nodules with size between 4 and 10 mm 
with any Volume Doubling Time (VDT) not candidate to surgical excision and/or   
 subsolid (non solid or partially solid) nodule larger than 10 mm with VDT higher than 400 days and not candidate to surgical excision. 
 
4.1.5 All nodules should be persistent at least after three months follow up with CT; a reduction up to 
15% of the diameter of the largest target nodule from the previous CT scan is allowed  4.1.6 All current smokers should accept to receive support for smoking cessation 
 
4.1.7 ECOG performance status ≤1 (Karnofsky ≥70%; see Appendix A) 
 4.1.8 Participants must have normal or gan and marrow function as defined below: 
Leukocytes   ≥3,000/microliter 
Absolute neutrophil count ≥1,500/microliter 
Platelets   ≥100,000/microliter 
Total bilirubin   ≤2 × institutional ULN and/or history of Gilbert’s syndrome  
AST (SGOT)/ALT (SGPT) ≤1.5 × institutional ULN 
Serum creatinine  ≤ institutional ULN 
 
4.1.9 The effects of Aspirin on the developing huma n fetus at the recommended therapeutic dose are 
unknown. For this reason and because  acetyl salicylic acid (ASA)  is known to be teratogenic, women of 
child-bearing potential (from first menstruation to 1 y ear after last menstruation) must agree to use 
adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and 
for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should 
inform her study physician immediately. 
 4.1.10  Ability to understand and the willingness to sign a written informed consent document. 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –16– 
05/21/2013  4.1.11  Signed informed consent. 
 
4.2 Exclusion Criteria 
 
4.2.1 Subjects with chronic treatment (at least twi ce/week for more than 3 months) with Aspirin or 
other NSAIDs.  4.2.2 History of allergic reactions attributed to compounds of similar chemical or biological 
composition to aspirin, NSAIDs, COX2 inhibitors.  
4.2.3 Invasive malignancy (with the exclusion of  basal cell carcinoma or skin squamous cell 
carcinoma) diagnosed during the last 2 years before randomization; stage I-II invasive malignancies that 
were diagnosed more than 2 years prior to randomization and have been treated curatively are allowed as 
long as all treatment is finished at least 18 months prior to randomization.  
4.2.4 History of therapeutic doses of anticoagulan ts including warfarin and low molecular weight 
Heparin (e.g. for prior deep venous thrombosis and pulmonary embolisms) in the preceding year. 
 
4.2.5 Uncontrolled intercurrent illness including, bu t not limited to, ongoing or active infection, 
symptomatic congestive heart failure, unstable angi na pectoris, cardiac arrhythmia, or psychiatric 
illness/social situations that would lim it compliance with study requirements. 
 4.2.6 Pregnant women are excluded from this study because Aspirin is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in 
nursing infants secondary to treatment of the mother w ith Aspirin, breastfeeding should be discontinued if 
the mother is treated with Aspirin.  4.2.7 Individual may not be receiving any other inves tigational agents, antiplatelet agents (e.g. aspirin, 
clopidogrel (plavix or others)), anticoagulants (e.g . heparin or heparinoids, coumadin, or others), 
metotrexate, lithium. 
 
4.2.8 Participants with bleeding diathesis, history of gastric/duodenal ulcers in the last 5 years, NSAID-precipitated bronchospasm, patients unwilling or unab le to limit alcohol consumption to i.e. ≤ 3 alcohol 
drinks a day.  4.2.9 Participants who in the opinion of the PI will be at higher risk of ASA-related complications.  
 4.2.10 Participants with known inability to  adequately absorb oral medication.  
 
4.3 Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethni c groups will be eligible for this trial. However, 
given that the distribution of the Italian population ma inly consists of white Caucasians (about 93%), we 
expect very few subjects of different ethnic background to be enrolled in the screening. The gender 
distribution among the Cosmos 2 screening populat ion is about 65% and 35% for men and women, 
respectively and we expect a similar distribution in  the chemoprevention stud y. Detailed information 
about distribution is reported in the DCP Protocol Submission Worksheet (PSW).  
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –17– 
05/21/2013  4.4 Recruitment and Retention Plan 
 
The projected number of eligible subjects in the entire cohort of 8,000 individuals undergoing annual 
screening at EIO will be close to 600. Considering that 20% of subjects will be excluded because of 
ongoing treatment with Aspirin, the eligible pool will include about 480 subjects. Accrual rate is expected 
to be no less than 32% of the predicted pool. This pe rcentage is higher than the average recruitment rate 
in chemoprevention trials in healthy subjects (average 10%), but is reasonable given that the population is 
represented by highly motivat ed volunteers and previous EIO screen ing compliance has been higher than 
97%. This would allow to consent about 150 people, whose slides will be re-revi ewed and re-measured by 
a study dedicated radiologist and pulmonologist. It is expected that approximately 128, or 80% of 
consented individuals, will meet all eligibility criteri a for the protocol and will be randomized. Since the 
Cosmos 2 trial is a five year prot ocol with annual low-dose CT scans, we will have the opportunity to pre-
screen the individuals participating in the Cosmos trial for eligibility and to approach them with the 
present protocol at the time of their next scheduled Cosmos trial-directed CT scan that falls within the 
window of our trial accrual period. Additionally, there will be indi vidulas who develop new small nodules 
for the first time while participating in the Cosmos  protocol. Such individuals will return per Cosmos 
protocol for a repeat CT scan in 3 months, and if they  meet the inclusion criteria of the present trial after 
the repeat CT scan, they will also be captured.  MDACC launched its Lung Cancer Screening Program in  2011. To date, nearly 800 participants have 
been screened averaging approximately 20-30 screened pa rticipants per month. An additional resource for 
screening CTs is the active protocol entitled “ Biospecimen Banking and Biomarker Validation for Lung 
Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening ” which has 
194 participants currently enrolled. A lthough literature indicates the freque ncy of eligible lesions is 
approximately 30%, MDACC’s experience is slightly l ess at 10% (2-3 participants per month) identified 
by low dose screening CT scan.  From this population, it is anticipated the Lung Cancer Screening program may enroll approx. 1 eligible participant per month after evaluation of other eligibility criteria.  
However, with the inclusion of lesions identified by  diagnostic CT scan, MDACC’ s large cancer survivor 
population offers a larger pool of potentially elig ible participants undergoing CTs for surveillance. 
 
Pre-Initiation phase  
 
Both at IEO and MDACC, subjects with persistent  subsolid lung nodules detected during any of the 
screening programs are potentially eligible for the tria l and will be identified as potential candidates for 
the study by the local Lung Cancer Screening program coordinator.  In addition, subjects with subsolid 
lesions identified outside the context of a screening pr ogram will be indicated to the research staff by the 
collaborating radiologists creating a future recruitmen t resource.  While waiting for the subsequent CT 
scan, the potential candidate will be given a leaflet about  the possibility of being contacted for taking part 
in a prevention trial. 
 
Active Recruitment phase  
At EIO, after the evaluation of the CT scan by the radiologist and the thoracic surgeon (Co-PI), and the 
verification of all inclusion criteria, the potential candi date will be contacted by the staff of the Division 
of Cancer Prevention and Genetics for the first phone interview. Each subject will be given a unique and 
consecutive ID number (four digits). The trial design w ill be explained and availab ility to participate will 
be asked. Candidates accepting to participate or interested in the study will be invited for a visit at EIO for informed consent and baseline visit.  At MDACC, after the evaluation of the CT scan by the thoracic radiologist (Co-PI), and the verification 
of all inclusion criteria, the potential participant will be contacted by the MDACC staff for the first phone 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –18– 
05/21/2013  interview. The study design, treatment plan, procedures, follow-up schedule, risks, side effects and 
potential benefits will be discussed with the potential participants.  Interested participants will be scheduled for informed consent and baseline visits in the Cancer Prevention Center.  Each subject will be 
given a unique and consecutive ID number (four digits).  
Retention phase (which include adherence strategies)   
The retention phase will be identical between EIO and MD Anderson.  Participants will be scheduled for 
periodic clinic visits (at 0, 6 a nd 12 months) during which a complete physical exam and lab tests will be 
performed. At months 1, 3 and 9 subjects will be contacted by phone to evaluate self-reported 
compliance/adherence to the treatment and toxicity. In  addition they will be reminded about the visit, CT 
scan and blood and urine samples at month 6 and 12.  
 Recruitment and retention effort will be evaluated routinely by the site coordinator and the study staff. It 
can be modified as necessary to promote rapid accrua l and to assure maximally high retention rate of 
participants.   
5. AGENT ADMINISTRATION 
 Drug will be administered on an outpatient basis. Reported adverse events and potential risks are 
described in Section 6.2.  
 
5.1 Dose Regimen and Dose Groups 
 Group 1 
Agent: Aspirin 
Daily doses: one dose of 100 mg once a day Duration: one year  Group 2 
Agent: placebo 
Daily doses: one dose once a day Duration: one year 
 
5.2 Aspirin  Administration 
 
At EIO, Dr Bonanni (PI) will be responsible for drug administration. He can delegate the colleagues of the Division of Cancer Prevention and Genetics (MDs and research nurses) to administer the agent on his 
behalf.  At MD Anderson, Dr Bevers (MD Anderson Site PI) w ill be responsible for drug administration. She can 
delegate to MDACC site collaborators to administer  agent on her behalf as noted in the Delegation of 
Authority log. 
 
Subjects will receive a 7-month supply of the drug/pl acebo as outlined in the clinical procedure schema 
(see paragraph 7.1. for a detailed description). Each kit contains of 210 tablets (7 bottles of 30 tables 
each) of aspirin 100 mg or placebo.  
Subjects will be advised to take aspirin after food. 
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –19– 
05/21/2013  5.3 Run-in Procedures  
 
No run-in procedure will take place in the present protocol. 
 
5.4 Contraindications 
 
Aspirin should not be taken by people  who are allergic to ibuprofen or  naproxen, or who have salicylate 
intolerance or a more generalized drug intolerance to non-steroidal anti-inflammatory drugs (NSAIDs), 
and caution should be exercised in those with asthma or NSAID-precipitated bronchospasm. Owing to its 
effect on the stomach lining, manufacturers recomme nd people with peptic ulcers, mild diabetes, or 
gastritis seek medical advice before using aspirin. Even  if none of these conditions is present, the risk of 
stomach bleeding is still increased when aspirin is taken with alcohol or warfarin. Patients with hemophilia or other bleeding tendencies should not take  aspirin or other salicylates. Aspirin is known to 
cause haemolytic anemia in people who have the genetic disease glucose-6-phosphate dehydrogenase deficiency, particularly in large doses and dependi ng on the severity of the disease. People with kidney 
disease, hyperuricemia, or gout should not take aspir in because it inhibits the kidneys' ability to excrete 
uric acid, and thus may exacerbate these conditions.  
 
5.5 Concomitant Medications 
 
Other NSAIDs or glucocorticostero ids should be avoided or limited.  Any use of systemic or topic 
NSAIDs or glucocorticosteroids s hould be clearly documented (time,  doses, routes, indications) and 
followed regularly. 
 
If a participant requires pain relievers or antipyr etics, the use of non-NSAIDs, e.g., acetaminophen, 
should be encouraged. It is not necessary to break th e blind in most situations. A protonic pump inhibitor 
(PPI, omeprazole 20 mg/day tablet) will be added during the period of any NSAIDs or 
glucocorticosteroids treatment and will be stopped once NSAIDs or gluc ocorticosteroids are withdrawn. 
 
Short courses of systemic NSAIDs or glucocorticos teroids (defined as up to 2 weeks at a time) are 
allowed. No more than 1 month total of off-protoco l NSAIDs or glucocorticosteroidsis allowed in a 6 
months period. If it is anticipated that continuous NS AIDs or glucocorticosteroids will be needed or if 
more than 1 month of NSAIDS or glucocorticosteroids occurs during a 6 months period, the participant 
will stop study drug. However, since the participant will still undergo his/her yearly scan, they can still be 
assessed in an intent-to-treat analysis and thus do not come off the study. Non systemic 
glucocorticosteroids use is allo wed without time restrictions. 
 
All medications (prescription and ove r-the-counter), vitamin and mineral supplements, and/or herbs taken 
by the participant will be documented on the concomitant medication CRF and will include: 1) start and 
stop date, dose and route of administration, and indication. Medications taken for a procedure ( e.g., 
biopsy) should also be included.  
5.6 Dose Modification 
 
Subjects will be asked to maintain the full dose throughout the treatme nt period. However, should some 
toxicity appears, dose modification will be applied and recorded. 
 Toxicity will be evaluated at each visit using the most recent version of the NCI terminology criteria 
(CTCAE version 4.0.3, published 06/14/2010).  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –20– 
05/21/2013  If grade 1 toxicity occurs, the patient will be mainta ined on full dose. Toxicity will be checked depending 
on clinical relevance.  
 
In case of grade 2 toxicity or higher, the dose will be  changed according to the potential relationship to 
study drug as listed in the table below . 
 
 
Toxicity Attribution to study drug 
Grade Unrelated Unlikely Possible Probable Definite 
1 C C C C C 
2 C C S-R0 S-R0 S-R1 
3 S-R2 S-R2 S-R1 W W 
4 S-R2 S-R2 W W W 
 
C =  Continue drug 
 S-R
0  = Stop drug until toxicity reaches grade 1 or lower, then restart drug at full dose (100 mg/day). If 
toxicity resumes, stop drug again until toxicity reaches grade 1 or lower, and then restart at alternate day 
and maintain the reduced dose. 
 S-R
1 = Stop drug until toxicity reaches grade 1 or lowe r, then reduce drug by 50% (100 mg at alternate 
day) and maintain the reduced dose.  
S-R
2 = Stop drug until toxicity reaches grade 1 or lowe r, then reduce drug by 50% (100 mg at alternate 
day) for 1 month. If toxicity is no more than grade 1, restart drug at full dose (100 mg/day). If toxicity 
resumes after reintroduction of full dose, stop drug agai n until toxicity reaches grade 1 or lower and then 
reduce drug by 50% (100 mg at alternate day) and maintain this dose. No further reductions will be 
permitted and patients with returning toxi cities will be removed from the study. 
 
W =  Withdrawal 
 For dyspepsia and GERD management only, a PPI,) will be added.  In case of dyspepsia grade 1 (G1), PPI will be added for two weeks. If remission, PPI will be stopped. If 
symptom persists or recurs, it will be defined as > grade 2 (G2). 
In case of dyspepsia > G2, the symptom will be managed as follows: 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendm ent 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –21– 
05/21/2013   
 
The clinical investigators of the study may be helped in their decisions by consultation of other specialists 
(Gastroenterologist).  
 
5.7 Adherence/Compliance 
 
Estimates for patient non-adherence to various med ical regimens range from 20% to 100%, and some 
authorities have come to view the difficulty of guara nteeing patient adherence as one of the most serious 
problems facing medical practice today. Recent data from ongoing chemoprevention studies have 
estimated adherence to be between 60% and 100%. The disparity between the highest and lowest 
estimates may largely be attributed to methodology,  given that the assessment of adherence remains 
problematic - there is as of yet no 'gold standard' to  measure patient adherence. Because no such gauge 
exists, we propose the use of multiple methods of a dherence monitoring: subject self-reporting, calendar 
completion and dose count.  
 Although drug concentration will not be measured in the blood, compliance will be monitored in the 
following ways:  
Patient Self-Report: The patient's history, the most direct source of information, is the most widely 
employed measure of a patient's adherence to thei r medical regimen. However, patient self-reporting has 

DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –22– 
05/21/2013  been criticized as being too subjective, with patient s tending to over-report their adherence by as much as 
two to fourfold. Positive information is helpful, but false negatives are common.  
 
Calendar completion : Each subject will be provided a 7-mont h calendar as a reminder of drug intake 
(Appendix B). Each subject will be asked to cross th e corresponding day of the calendar (1 cross for each 
tablet, i.e. 1 cross per day). Subjects are asked to fill the calendar and some additional space will be left 
for patient’s notes. Each calendar will be returned at the next scheduled visit. 
 Dose count: Each subject will receive a 7-month supply of the drug or placebo and will be asked to return 
all full and empty bottles. Compliance will be measured as follows: number of tablets taken (i.e., number of tablets given-number of tablets returned)/number of tablets that should have been taken during that period of time. In cases where the tablets are not returned, the co mpliance has to be calculated from the calendar. 
 
Serum Thromboxane (TXB2): As an additional measure of compliance, we will evaluate the concentration 
of serum TXB2, a reliable marker of aspirin use42. 
 
The chemoprevention research nurse and the physicians  will provide education for subjects, indicating 
when and how should the tablets be administered (gener al measures to reduce risk of GI adverse effects). 
 In case of concomitant medications, subjects are asked to contact the chemoprevention staff in order to check whether any potential interference is expected. Data on drug suspension or interruption will be reported into the CRFs. 
 
 
6. PHARMACEUTICAL INFORMATION 
 
6.1 Study Agent (IND #, IND Sponsor) 
 
FDA has determined that the study is exempt from the IND requirement  
 
6.2 Reported Adverse Events and Potential Risks 
 
Potential risks and rare side effects related to the treatment can be summarized in the following four 
major categories: 
 
• Upset stomach and heartburn. 
 • Easy bruising/bleeding, difficulty hearing, ringing in the ears, change in the amount of urine, 
persistent or severe nausea/vomiting, unexplained tired ness, dizziness, dark urine, yellowing eyes/skin. 
 • Black/tarry stools, persistent or severe stomach /abdominal pain, vomit that looks like coffee 
grounds, slurred speech, weakness on one side of th e body, sudden vision changes or severe headache. 
 
• Rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –23– 
05/21/2013  6.3  Availability 
 
Bulk aspirin and matching placebo will be manufactur ed and supplied by Bayer Europe, using a dose 
currently available on the European market.  Packaging and labeling will be performed by Monteresearch 
srl, Bollate, Italy and labeling performed by MRIGlobal for US supplies. 
 
Aspirin  is provided to the EIO under a Clini cal Trials Agreement (CTA) between  Bayer Europe and the 
EIO (see §12.7) . 
 
6.4 Agent Distribution 
 
Agents will only be released by NCI, DCP after documentation of IRB appr oval of the DCP-approved 
protocol and consent is provided to DCP and the co llection of all Essential Documents is complete (see 
DCP website for description of Essential Documents).   
EIO 
Bayer Europe will release active drug and matching pl acebo to the EIO only after documentation of IRB 
approval and a specific contract has been signed by the EIO representative. The distributor will be Bayer 
Europe.  Bayer will ship the unmasked drug to the exte rnal Pharmacy service appointed by the EIO 
(Monteresearch srl, Bollate, Italy) that will be r esponsible for re-labeling and packaging the bottles 
according to protocol requirements. Each bottle c ontains 30 tablets. The pharmacy service will provide 
blinded study agent to investigators with a current FDA form 1572 filed with DCP. Drug will not be used 
or distributed out of the present protocol.  
 
MD Anderson 
For US clinical supplies, the packaged drug will be labeled in US English by the NCI DCP repository, 
MRIGlobal. The NCI DCP repository will dist ribute the clinical material to MDACC. 
 NCI, DCP-supplied agents may be requested by the Inv estigator (or their author ized designees) at each 
Organization. DCP guidelines require that the agent be shipped directly to the institution or site where the 
agent will be prepared and administered. DCP does not permit the transfer of agents between institutions 
(unless prior approval from DCP is obtained). DCP do es not automatically ship agents; the site must 
make a request. Agents are requested by completing the DCP Clinical Drug Request form (NIH-986) (to 
include complete shipping contact information) and faxing or mailing the form to the DCP agent 
repository contractor:  
John Cookinham  MRIGlobal DCP Repository 425 Volker Blvd. Kansas City, MO 64110  Phone: (816) 360-5369 
FAX: (816) 753-5359 
 Emergency Telephone: (816) 360-3800 
 
 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –24– 
05/21/2013  6.5  Agent Accountability   
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of 
the inventory and disposition of all agents receive d from DCP using the NCI Drug Accountability Record 
Form (DARF) or an institutionally-approved accountability system. The Investigator is required to maintain adequate records of receipt, dispensing and final disposition of study agent. Include on receipt record from whom the agent was received and to whom  study agent was shipped, date, quantity and batch 
or lot number. On dispensing record, note quantities and dates study agent was dispensed to and returned by each participant. At EIO, this responsibility has been delegated to EIO Pharmacy. At MD Anderson, 
this responsibility has been delegated to MDACC Investigational Pharmacy.  
 
6.6 Packaging and Labeling  
 
Aspirin and matching placebo will be provided to EI O by Bayer Europe as a bulk shipment, but labeled 
and packaged by an external Ph armacy where they will be stored until delivery. An undisclosed 
randomization list will be provided by the statistician to  the dedicated Pharmacist. Each package consists 
of a 7-month supply of the drug or placebo. Each box contains seven bottles with 30 tablets each. Each box will be labeled with the following information: EIO study number (S-XXX), randomization number 
(3 digits), PI’s name and phone number, number of total doses, daily dose and schedule, lot numbers and 
expiring dates, specific instruction such as storage temp erature, indication to keep the bottle out of reach 
of children. Subject’s identification number will not be  reported on drug packages. The same instructions 
will be stuck in the external part of the box packag e. Half of the label will be removed from the box and 
stuck into the drug delivery CRF to confirm appropr iate drug has been administered to the subject.  
 For clinical supplies in the US, the NCI, DCP repository (MRIGlobal) will perform the product labeling, using US English labels, and will stor e the product for distribution to MDACC.  
 
6.7 Storage 
 
Study drug will be stored in a secure loca tion, at controlled room temperature (59°F and 86°F) under low 
humidity. 
 
6.8 Registration/Randomization 
 
Baseline/ Registration into the DMI Database:   
Participants will be screened, consented and, once info rmed consent has been signed, participants will be 
registered into the DMI database.  The DMI databa se will assign a participant’s PID upon completion of 
the registration process.  
 
Randomization :  
Participants will be assigned a randomization numb er once the following has been accomplished: 
eligibility has been verified at the site level, eligib ility has been confirmed by the site PI, and eligibility 
CRF has been entered into the DMI web application.   The randomization numbe r will be generated by the 
database and assigned to the participant. Refer to  Section 13.2 for details of randomization.  
 
Baseline/Registration/Randomization into site-specific databases: 
The DMI is the database of record for the study.  Registration and randomization should occur per the 
procedures outlined above. If the site staff need to ente r study data into site-specific electronic databases 
per their institutional requirements, they should do so  in accordance with thei r institutional policies and 
procedures. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –25– 
05/21/2013   
Appropriate CRFs must be completed for any participan t who signs an informed consent. If a consented 
participant is a screen failure and deemed ineligible, the following CRFs must be completed: 1) the 
Registration CRF with the eligibility box checked “ no”, 2) the Inclusion and Exclusion CRFs showing 
why the participant is ineligible, 3) the Off-Study CRF, 4) the Adverse Event CRF, 5) the Concomitant 
Medication CRF and 6) the Verification CRF. If no Adve rse Event and/or Concomitant Medications were 
assessed by the time the participant is deemed inel igible, the “NONE” box will be checked to complete 
both CRFs. All participants who sign an informed c onsent must formally go off study. All participant 
registration information will be entered into DMI. If  a participant experiences a serious adverse event 
during the screening process, an SAE form must be completed. 
 
6.9 Blinding and Unblinding Methods 
 
 Participants will be blinded to aspirin or placebo. 
 The Statistician and the Study Pharmacist w ill not be blinded to Aspirin or placebo. 
 All other Investigators will be blinded to Aspirin or placebo. 
 The MDACC Data and Safety Monitoring Board will also be blinded unless unblinding is 
warranted (the reasons for unblinding are outlined below). 
 All participants will take 1 tablet per day of aspirin/matching placebo. 
 Study assignments will be unblinded to the Study Inv estigators and Site Coor dinators after all of 
the data are collected and the study database has been locked. Unblinding will also occur if the 
participant’s physician deems that unblinding is necessary, such as in the case of unacceptable toxicity 
thought to be related to the study agent or progressive disease, or if the participant becomes pregnant.  Unblinding will only take place after consultati on with the NCI, DCP Task Order Monitor Eva 
Szabo, MD.  If unblinding is indicated prior to the completi on of the study, it will be conducted as follows: 
 The Site PI contacts the Protocol Chairman (the Protocol Principal Investigator) and 
requests the participant’s treat ment status be unblinded. 
 The Protocol Chairman (the Protocol Principal Investigator) contacts the NCI, DCP Task 
Order Monitor (Medical Monitor) and request s the participant’s treatment status be 
unblinded. The Protocol Chairman then conveys the Task Order Monitor’s decision to the Site PI. The Site PI then proceeds with unblinding as written out below.  
 If the NCI Task Order Monitor cannot be reached and the participant requires emergency care, the Protocol Chairman (the Protocol Pr incipal Investigator) may authorize the site 
PI to break the blind. 
 If the Site PI is unable to reach the Protocol Chairman and the participant requires emergency care, then the Site PI must proceed with unblinding as written out below.  
 The Site PI requests the participant’s treat ment status be unblinded by the research 
pharmacist (or designated individual responsible for dispensing drug). 
 The Site PI officially takes the participant off-study.  
 The date and reason for breaking the blind must be submitted by the Site PI to the Protocol Chairman, Bernardo Bonanni, MD, as soon as possible.  
 It is the responsibility of the Study Chairman to repo rt the date and reason for breaking the blind to 
the NCI Task Order Monitor , Eva Szabo, MD , as soon as possible.  
 The date and reason for breaking the blind mu st be submitted by the Study Chairman to 
the MD Anderson Consortium Principal Investigator, Powel H. Brown, MD, PhD, or 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –26– 
05/21/2013  designee as soon as possible via email to phbrown@mdanderson.org  and 
lavornik@mdanderson.org  or phone at (713) 792-4509. 
 The date and the reason for breaking the blind will be reported by the MD Anderson 
Consortium Principal Investigator or desi gnee to the MD Anderson DSMB as soon as 
possible. 
 
6.10 Agent Destruction/Disposal  
 
EIO 
At the completion of investigation at EIO, all unused study agent together with all returned tablets will be returned to the Pharmacy Service a nd kept till destruction. Documentation of disposal and destruction will 
be kept until the end of the trial.  
 
MDACC 
At the completion of investigation at MD Anderson, all unused study agent will be  returned to NCI, DCP 
Repository according to the DCP “Guidelines for AG ENT RETURNS” and using the DCP form “Return 
Drug List”.  The guidelines and the form are available on the DCP website.  
 
 7. CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 Schedule of Events 
 
On a weekly basis, all subjects participating in  the ongoing IEO screening programs COSMOS 1 and 
COSMOS2 presenting lung nodules are discussed during mu ltidisciplinary meetings involving radiologist 
and clinicians in order to assess the most  appropriate monitoring schedule.  
In addition, subjects with eligible subsolid lesions identified outside the context of a screening program 
will be discussed to select potential participants.  Subjects presenting one or more persistent subsolid  lung nodules according to the inclusion criteria (see 
par 4.1) are eligible for this chemoprevention trial.  At EIO, potential candidates will be contacted by 
phone by trained personnel illustrating the possibility  of taking part in a chemoprevention trial and 
scheduling an appointment for an outpatient visit at the Institute. Randomization should be performed 
within 2 months (i.e., 61 days) from the CT scan. An exception may be done for those subjects with 
nodules who are eligible at the CT scan performed 3 months apart: in order to maintain 12 months 
treatment period, these subjects will be randomized within 6 weeks (i.e. 42 days) and will repeat the CT scan 12 months after.  
 
At MDACC, subjects with persistent subsolid lung nodules detected during any of the screening programs are potentially eligible for the trial a nd will be identified as potential candidates for the 
study by the Lung Cancer Screening program coordi nator.  In addition, subjects with subsolid 
lesions identified outside the context of a screeni ng program will be provided to the research staff 
by the collaborating radiologists creating a futu re recruitment resource upon subsequent CT for 
stability.  While waiting for subsequent CT scan, the potential candidate will be given a leaflet 
about the possibility of being contacted for taking pa rt in a prevention trial. Both standard dose and 
low dose CT scans are allowed provided that the same procedure is used at both time points.
 
Baseline and Randomization:  
 Signed informed consent. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –27– 
05/21/2013   Collection of a blood samples (safety including -HCG if applicable, biomarkers including TXB2 
and biorepository), urine samples (biomarkers), phys ical exam and medical history including baseline 
symptoms; concomitant medications; confirmation of eligibility criteria 
 Participants are randomized to receive either st udy agent or placebo and will be given a 7-month 
supply of drug or placebo (a kit containing 7 bottles of  drug or placebo, with 30 tablets in each bottle, 1 
tablet per day) together with a daily calendar.  
 Month 1 (+/- 1 weeks from randomization): 
Phone contact in order to: 
 record concomitant medications and r ecord and evaluate adverse events; 
 record self-reported compliance. 
 
Month 3 (+/- 2 weeks from randomization):  
Phone contact in order to: 
 record concomitant medications and r ecord and evaluate adverse events; 
 record self-reported compliance. 
 confirm date of the next schedule clinic visit and blood/urine tests 
 CT scan if determined to be need ed during multidisciplinary meetings 
 
Participant will be asked to return used and unused boxes at the month 6 visit. 
 
Month 6 (+/- 2 weeks from randomization): 
 Participants will undergo physical exam, v ital signs, weight, lab test (including -HCG, if 
applicable) and biological sample collection (blood , urine) for biomarker measurement including TXB2. 
 Concomitant medications will be r ecorded and adverse events will be recorded and evaluated.  
 Compliance will be measured (subjects will be asked  to return both used and unused bottles as well 
as calendar).  
 CT scan if determined to be need ed during multidisciplinary meetings 
 
A 7-month supply of drug or placebo will be provided (a  kit containing 7 bottles of drug or placebo, with 
30 tablets in each bottle, 1 tablet per day).  
 
Month 9 (+/- 2 weeks from randomization):   
Phone contact in order to: 
 confirm date of the next CT scan and month 12 clinic visit and ; 
 record concomitant medications and r ecord and evaluate adverse events; 
 record self-reported compliance. 
 
Month 12 (+/- 2 weeks from randomization): 
 Participants will undergo physical exam, vital signs, weight, lab test and biological sample collection 
(blood and urine) for biomarker measurement including TXB2 and biorepository. 
 Concomitant medications will be recorded  and toxicity will be evaluated.  
 Compliance will be measured (subjects will be asked  to return both used and unused bottles as well 
as the calendar).   CT scan will be performed. 
  
Month 13: Phone contact; adverse ev ents and concomitant medication w ill be recorded and evaluated. 
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –28– 
05/21/2013  SCHEDULE OF EVENTS 
 
Evaluation/ Procedure Pre-
study 
evalu
ation Baseline 
Visit/Reg
istration Randomi 
zation Month 
1 
 Month 
3  
 Month 
6 
visit Month 
9 
 Month 
12  
visit Month 
13 
 Early 
Termina-
tion 
Informed Consent  X         
Assess pre study 
Eligibility (CT scan) X          
Assess Eligibility   X         
Medical History  X         
Physical Exam/ 
height/weight/ vital signs  X    X  X  X 
Interim medical history      X 
  
 X 
  X 
Tobacco use assessment  X  
    X 
   X 
  X 
Laboratory Tests  X 
    X 
  X 
  X 
 
Biomarkers*§ (blood, urine)   X    X  X   
Biorepository (blood)   X      X   
CT scan     (X) (X)  X   
Concomitant Medications  X  X X X X X X X 
Baseline symptoms  X         
Dispense Study Agent   X   X 
     
Collect study agent 
      X  X  X 
Compliance    X° X° X X° X  X 
Review Agent Diary/Record   X   X  X  X 
Adverse Events    X X X X X X X 
Phone contact    X X  X  X  
§Biomarkers collection at baseline, 6 and 12 month visit requires the subiect to have fasted for at least 6 hours and includes TXB2 measurement; *Blood for 
miRNA and urine for LTE4 and PGEM will be collected and measured at baseline and month 12 only; ° review of self reported compl iance; Serum pregnancy test 
will be done only on potentially fertile women by -HCG measurement;  if determined to be needed duri ng COSMOS multidisciplinary meetings 
 
 
7.2 Prestudy Evaluation/Baseline Visit/Registration 
 
Pre study evaluation is: 
 Measurement of subsolid nodules detected at an y qualifying CT scan (for details see section 7.6) 
 Baseline exams are:  
 Fasting blood lab tests (hemogram, AST, ALT, Na, K,  glucose, BUN, total bilirubin, Cl, Ca, alkaline 
phosphatase, creatinine, -HCG, if applicable) 
 Physical exam and medical history; for the purpose of the present study, minimal requirements for the 
physical exam visit include the following body/system sites: appearance, chest, lungs, heart and abdomen. 
 Fasting (at least 6 hours) blood sample collection fo r biomarkers, biorepository and baseline level of 
serum TXB2 
 Urine sample collection for urinary creatinine and for biomarkers 
 At baseline clinic visit, participants will be instru cted on the importance of drug compliance. Participants 
will be provided and instructed on the use of a pill di ary to be completed daily, signed and dated by the 
participant. Participants will be informed that a p ill count will be conducted on their study medication use 
so that their study medication bottle with remaining ta blets must accompany them in the subsequent clinic 
visit. 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –29– 
05/21/2013  7.3 Evaluation During Study Intervention 
 
During study intervention, participan ts will undergo physical exam, interim history, vital signs, weight, 
tobacco use assessment, in a dedicated outpatient clin ic at month 6. Phone contact will occur on month 1, 
3, and 9. 
 
Safety blood lab tests (hemogram, AST, ALT, Na, K, glucose, BUN, total bilirubin, Cl, Ca, alkaline 
phosphatase, creatinine, -HCG, if applicable) will be performed at month 6. 
 
Fasting (at least 6 hours) biological samples (blood and urine) will be collected at month 6 for biomarker measurement including TXB2. Samples will be stored until measurement.   
7.4 Evaluation at Completion of Study Intervention 
 
Participants will undergo CT scan, physical exam, interim history, vital signs, weight, tobacco use assessment, in a dedicated outpatient clinic at month 12.  
 
Safety lab tests (hemogram, AST, ALT, Na, K, glucose, BUN, Total Bilirubin, Cl, Ca, Alkaline 
phosphatase, creatinine, -HCG, if applicable) will be  performed at month 12. 
 Fasting (at least 6 hours) blood samples will be co llected at month 12 for biomarkers measurement 
including TXB2 and biorepository. Samples will be stored till measurement.  
 Urine sample will be collected fo r urinary creatinine and for biomarkers. Samples will be stored till 
measurement.  
 7.5 Post-intervention Follow-up Period  
Participants will be contacted with a phone call at month 13, i.e. 1 month after the final CT scan, to check 
about adverse events and concomitant medication. 
 After that, subjects will continue the CT scan evaluation as needed 
 
7.6 Methods for Clinical Procedures  
 
Assessment of lung nodules with low dose CT scan at IEO  
 
Investigations will be performed with low-dose CT  scans (average effective dose <1.5 mSv, without 
contrast medium), with a multidetector (64 sli ces) CT scanner (CT750 HD/Optima 660, General Electric 
Healthcare, USA) with the following parameters: 
• 120 Kvp, 30 mA 
 Matrix 512x 512 
• pitch 1.75 
• 2.5 mm thickness 
 Soft tissue algorithm 
• single breath, in respiratory apnoea 
• retro-reconstruction at 1.25 mm interval • at the end of a session of 15 - 20 subjects the in vestigations will be sent to the workstation and 
archived both on hard-disk and on CD in DICOM format. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –30– 
05/21/2013  • multiplannar reconstruction and 3-dimensional volume reconstruction will be performed on the 
workstation (Advantage Windows 4.2, General Electric medical system) 
 
Nodule volumes and volume doubling time (VDT) will be automatically calculated by Lung VCAR 
specific software (GE healthcare). In absence of available volumetry by the software, VDT will be calculated by the following formula using the maximum diameter
43. 
 
VDT = log 10 2 x (difference in days between first CT and second CT) 
 3 x log 10 (difference in nodule size [mm] between first CT and second CT)  
 
Lung nodule maximum and mean density will be measured by the software lung VCAR (GE) before and 
after treatment.  Within 6 days an expert radiologist will read the images on the workstation through the windows for lung 
parenchyma (WW 1500, WL -650) and with MPVR (maximum projection visual resolution) reconstruction and mediastinum windows (WW 400, WL 40). A comparison between first year and 
baseline CT scan will be performed by Cosmos radiologists. All exams which show persistence of previous identified subdolid lung nodul es will be discussed in a specific meeting with a senior radiologist 
(chemoprevention trial-responsible) and a senior th oracic surgeon (chemoprevention trial-responsible) 
within 10 days of the CT investigation. Eligible  cases for the chemoprevention trial according to the 
criteria in section 4.1 and 4.2 are scheduled for the preliminary phone contact. 
 
Assessment of lung nodules with low dose CT scan at MDACC 
Investigations will be performed with low-dose CT  scans (average effective dose <1.5 mSv, without 
contrast medium), with a multidetector (64 slices) CT scanner (CT750 HD, General Electric Healthcare, USA) with the following parameters: 
• 120 Kvp, noise modulation, Radiation dose < 3mGy for standard size patient. 
Matrix 512x 512 •    2.5 mm, 1.25 mm and 0.625 mm thickness Soft tissue and lung algorithm •    single breath, in respiratory apnea 
•    retro-reconstruction at 50% interval 
•  multiplannar reconstruction at scanner.3-dimensional volume reconstruction performed with dedicated software .  
Assessment of lung nodules with standard chest CT  
Investigations will be performed with standard CT scans (with or without contrast medium), with 
multidetector scanner(16 or 64 slices): 
•     120 Kvp. Matrix 512x 512 •     2.5 mm thickness Soft tissue and lung algorithm 
•     single breath, in respiratory apnea 
•     retro-reconstruction at 1.25 slice interval •    multiplannar reconstruction at scanner.3-dimensi onal volume reconstruction performed with dedicated 
software .   
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –31– 
05/21/2013  8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
8.1 Primary Endpoint  
 
For the purposes of the primary endpoint, only sub-solid (non-solid or partially solid) nodules will be 
assessed. Target lesions are defined as non solid or pa rtially solid nodules persistent at least after 3 
months follow up with standard or low dose CT scan, at least 4 mm in size. Non target lesions include 
solid nodules (larger than 3.5 mm), new lesions at baseline (e.g., that were not present on prior CT) or non-solid or partially solid nodules < 4mm in size.  
 
The primary end-point will be the difference in sum of longest diameters of baseline target lesions in a person-specific analysis. New subsolid lesions identified during follow-up satisfying the same criteria for the definition of target lesion will also be included in the analysis. 
 
It has been assumed a -0.2 mm average reduction of th e sum of the longest diameter of all non-solid and 
partially-solid lesions at 12 months with respect to  baseline in the placebo arm and an expected average 
reduction of -1.0 mm in the aspirin group. 
8.2 Secondary Endpoints 
  
We will investigate the effects of aspirin on the fo llowing secondary end points: (see paragraph 13.5 for a 
detailed statistical analysis):  
 
Evaluation of response according to modified RECIST criteria: 
 
The per-lesion analysis will be done according to the Modified RECIST criteria: 
Complete Response (CR)= disappearance of the lesion 
Partial Response (PR) = shrinkage of >30% of the longest diameter 
Stable Disease (SD) = anything other than CR, PR or PD Progressive Disease (PD) = growth >20%, with a minimum increase of 2 mm 
 The per-subject analysis will be done according to Modified RECIST criteria: 
 
For single nodules a clinical meaningful shrinkage of 30% or more of the longest diameter will be 
considered as a treatment success after one year of  treatment as long as there are no new non-solid or 
partially solid nodules or nodules highly suspici ous for malignancy or shown to be malignant 
(modification to RECIST criteria). Growth of 20% or more with a minimum of 2 mm, will be considered 
progression.   
For multiple lesions the sum of the maximum diameters of all target nodules will be considered, using the 
same parameters to define success and progression (30%  or more decrease and 20% or more increase, 
respectively). In case of multiple lesions, treatment will be consid ered successful when a co mplete response (CR) or 
partial response (PR) occurs according to modified RECIST criteria, while treatment will be considered a 
failure when progression of disease (PD) or stable disease (SD) occurs according to the same criteria. 
Specifically: 
CR: disappearance of all target lesions, + no progression of non-target lesions + no appearance of new 
non-solid or partially solid lesions, and no appearan ce of new nodules highly suspicious for malignancy 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –32– 
05/21/2013  or shown to be malignant (even if solid); 
PR: CR for some target lesions + PR/SD for other target lesions + no PD or new lesions as described in 
CR above; or, PR (i.e., > 30% decrease in the sum of the longest diameter of target lesions, taking as 
reference the baseline sum longest diameter) for target lesions + no PD for non target lesions + no appeareance of new lesions as described in CR above; 
PD: PD (A >20% increase in the sum of the longest diameter of target lesions, taking as reference the 
smallest sum longest diameter record ed since the start of treatment) for target lesions irrespective of 
response of non target lesions; or PD for non target lesions irrespective of response for target lesions; or 
appearance of new non-solid or partially solid lesions or appearance of new nodules highly suspicious for 
malignancy or shown to be malignant irrespective of response of target or non target lesions; 
SD: neither sufficient shrinkage to qualify for PR  nor sufficient increase to qualify for PD, taking as 
reference the smallest sum longest diameter since the start of treatment. 
 All solid nodules will be considered in a separate se condary analyses, unless they are highly suspicious 
for malignancy or are actually shown to be malignant, in which case they will represent progressive disease (PD). Non-suspicious (stable solid nodules with clearly benign features) will not be considered in 
the analysis according to RECIST criteria
44  
Analysis of non target lesions  
Evaluation of number and size of non target l esions before and after treatment including : 
-Subsolid nodules less than 4 mm .  
-Solid nodules: evaluation of number and size of preexisting or new solid nodules will be performed. The analysis will be analogous to the analysis of non-so lid and partially solid nodules described above, but 
substituting solid lesions for subsolid lesions. In ad dition, a combined analysis of nonsolid and solid 
lesions (with solid lesions considered to  be non-target lesions) will be performed. 
- New nodules: A separate analysis examining new nodule appearance at 0 and 12 months  
- Cancer: the rate of cancer in each arm will be assessed.
 
 
Nodule density  
We will evaluate nodule density measured by qu antitative changes in mean and maximum Hounfields 
Unit (HU) before and after treatment.  
 
miRNA  
The effectiveness of the miRNA serum protocol will be evaluated by comparing the sensitivity, 
specificity and accuracy of miRNA to identify patient s with GGO or with partially solid nodules and to 
predict aspirin treatment response considering the LD CT screening protocol as the reference procedure. 
The ultimate goal is to evaluate if miRNA analysis in the serum can represent a new non-invasive test to 
identify patients with GGO or with partially solid nodules and to predict treatment response to low-dose 
aspirin.   
Additional biomarkers 
Additional biomarkers will include the modulation of  hs-CRP as marker of inflammation, the evaluation 
of urinary cotinine as marker of tobacco exposure and investigation of the potential effect of aspirin 
according to its concentration, the measurement of urinary PGEM and LTE4 normalized to urinary 
creatinine concentration. Serum TXB2 will be determ ined as a measure of compliance. Results will be 
compared between the two treatment arms (aspirin and placebo).  
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –33– 
05/21/2013  Tolerability 
Aspirin tolerability will be evaluated.  
 
8.3 Off-Agent Criteria  
 
Participants may stop taking study agent for the following reasons: completed the protocol-prescribed intervention, adverse event or serious adverse ev ent, inadequate agent supply, noncompliance, 
concomitant medications, medical contra indication. Participants will continue to be followed, if possible, 
for safety reasons and in order to collect endpoint data  according to the schedule of events. Subjects will 
not be replaced. 
 
8.4 Off-Study Criteria 
Participants may go ‘off-study’ for th e following reasons: the protocol inte rvention is completed, protocol 
violation, adverse event/serious adverse event, lost  to follow-up, physician decision (i.e., non-compliance, 
concomitant medication, medical cont raindication), participant withdrawal (i.e., withdraw consent), death, 
ineligibility or screening failure, disease progression or other reason.  
 
8.5 Study Termination 
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
  
9. CORRELATIVE/SPECIAL STUDIES 
 
9.1 Rationale for Methodology Selection  
 Blood 
miRNA analysis 
miRNA extraction and purification from serum (4.5 ml  of blood) will be done accordingly to standard 
procedure33. We will analyze approximately ~850 miRNAs using the TLDA qRT-PCR microfluidic cards 
(Applied Biosystems) and we will determine serum miRNA relative quantities using the ΔΔ Ct-method. 
Importantly, we will check the presence of hemoly sis in all serum sampl es collected for miRNA 
screening. This will be done before the miRNA extr action by visual inspection and by measuring the 
absorbance at 414nm45, and after analysis of the expression ratios of couples of miRNAs found by us and 
by others to be sensitive enough to reveal hidden hemolysis45. In addition, we will introduce spike-in 
synthetic miRNAs to be used as standard references in every sample screened. This will allow us to 
control either the efficiency of the extracti on procedure and of all the qRT-PCR reactions. 
Data analysis will be performed using R software ( http://www.r-project.org/ ) and SAS software 
(http://www.sas.com/) for correlation analysis with all other clinical, pathological and radiological 
parameters.  hs-CRP 
Serum concentrations of C-reactive protein as mark er of inflammation will be measured by means of 
commercially available assays. Serum samples from the same patient obtained at different time-points 
will be run in batches in order to  reduce analytical variability. Sta ndards for good laboratory practice are 
applied. Monitoring of precision and reproducibilit y will be performed by processing commercially 
available control samples and internal in- house prepared pool of samples in each run. 
 
Urine 
Urine concentrations of cotinine, prostaglandin E metabolite and leukotriene E4 will be measured by 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –34– 
05/21/2013  means of commercially available assays. Urine samples from the same patient obtained at different time-
points will be run in batches in order to reduce an alytical variability. Standards for good laboratory 
practice are applied. Monitoring of precision a nd reproducibility will be performed by processing 
commercially available control samples and internal in-house prepared pool of samples in each run.  
 
Cotinine 
We will use NicAlert® test (Nymox Pharmaceutical Corporation, Quebec, Canada)  to measure tobacco 
product exposure . The test is able to detect exposed to t obacco products such as cigarettes, pipes, or 
chewing tobacco within the past 48 hours. Second hand smoke exposure may cause a positive result in a 
non-user of tobacco products.  
NicAlert® is a semi-quantitative immunochromatographic assay for urinary cotinine measurements, that 
uses monoclonal antibody-coated gold particles and a series of avidity traps that allow quantification. The sample collection end of the strip contains gold par ticles coated with monoclonal antibodies to cotinine, a 
relatively long-lived metabolite of nicotine. The di stance the gold migrates on the strip is shown by a 
clear color change and provides an accurate measure of  the amount of cotinine in the sample. The cutoff 
concentration for the NicAlert
® test is 100 ng/mL. The NicAlert™ Negative Controls consist of cotinine-
free (NicAlert® Level "0") human preserved pathogen-free urine. The NicAlert® Positive Controls 
consists of cotinine-free urine spiked with cotinine to  concentrations of 400 ng/mL cotinine (Low Positive 
Control, NicAlert® level "4") and 2000 ng/mL cotinine (High Positive Control, NicAlert® level "6"). 
 
PGEM 
Because of the rapid metabolism of prostaglandin E 2 (PGE 2), the determination of the in vivo  biosynthesis 
is often best accomplished by the measurement of the concentration of PGE 2 metabolites. We will 
measure urinary concentrations of prostaglandi n E metabolites (PGEM) by a competitive enzyme 
immunoassay (EIA) kit purchased from Cayman (Cay man Chemical Co., Ann Arbor, Michigan, United 
States) that converts all major metabolites into a single stable derivative which is easily measurable by 
EIA. The assay is based on the competition between PGE 2 and PGE 2-acetylcholinesterase (AChE) 
conjugate (PGE 2 tracer) for a limited amount of PGE 2 monoclonal antibody. Because the concentration of 
the PGE 2 tracer is held constant while the concentration of PGE 2 varies, the amount of PGE 2 tracer that is 
able to bind the PGE 2 monoclonal antibody is inversely proportional to the concentration of PGE 2 in the 
well. This antibody complex PGE 2 binds to goat polyclonal anti-mouse IgG that has been previously 
attached to the well. The plate is washed to re move any unbound reagents and then Ellmans reagent 
(which contains the substrate to AChE) added to th e well. The product of this enzymatic reaction has a 
distinct yellow color that absorbs strongly at 4 12 nm. The intensity of this color, determined 
spectrophotometrically, is proportional to the amount of PGE 2 tracer bound to the well, which is inversely 
proportional to the amount of free PGE 2. 
We will check for interference by contaminants presen t in urine by 1:10 and 1:30 dilution of crude 
samples with phosphate-buffered saline. If the two different dilutions of the samples show good correlation (differ by 20% or less) in the final calculated PGE
2 concentration, purification is not required. 
If we do not see good correlation of serial dilutions, pur ification according to the purification protocol 
provided with the assay method will be applied. 
 
LTE4 
Urinary leukotriene E 4 (uLTE 4) will be determined by a competitive enzyme immnoassay kit (Cayman 
Chemical Co., Ann Arbor, Michigan, United States).  The assay is based on the competition between 
uLTE 4 and uLTE 4-acetylcholinesterase (AChE) conjugate (uLTE 4 tracer) for a limited amount of uLTE 4 
Antiserum. Because the concentration of the uLTE 4 tracer is held constant while the concentration of 
uLTE 4 varies, the amount of uLTE 4 tracer that is able to bind the uLTE 4 antiserum will be inversely 
proportional to the concentration of uLTE 4 in the well. This antibody uLTE 4 complex  binds to a mouse 
monoclonal anti-rabbit IgG that has been previously att ached to the well. The plate is washed to remove 
any unbound reagents and then Ellman’s reagent (whi ch contains the substrate to AChE) added to the 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –35– 
05/21/2013  well. The product of this enzymatic reaction has a distinct yellow color that absorbs strongly at 412 nm. 
The intensity of this color, determined spectr ophotometrically, is proportional to the amount of uLTE 4 
tracer bound to the well, which is inversel y proportional to the amount of free uLTE 4.  
We will check for interference by contaminants presen t in urine by 1:10 and 1:30 dilution of crude 
samples with phosphate-buffered saline. If the two different dilutions of the samples show good correlation (differ by 20% or less) in the final calculated uLTE
4 concentration, purification is not required. 
If we do not see good correlation of serial dilutions, pur ification according to the purification protocol 
provided with the assay method will be applied. 
 
TXB2 Serum concentration of thromboxane  B2 (TXB2) will be determined by a competitive enzyme linked 
immunosorbent assay (Neogen TM, Lexingotn, KY, USA). The assay is based on the competition 
between the enzyme conjugate and the TXB2 in the sample for a limited amount of binding sites on the 
antibody coated plate. The detection limit for the TXB2 assay is 4 pg/ml. 
 
 
BIOREPOSITORY 
DNA and RNA will be prepared and stored for future unspecified analyses for specific markers for whole 
genome DNA and RNA profiling. Samples will be stored at IEO Biobank and Biomolecular Resource Infrastructure (IBBRI). A specific institu tional informed consent will be used
. 
 
9.2 Comparable Methods  
 
We will use established and validated assays for determ ination of changes in biomarkers’ expression in 
this study. We plan to evaluate biomarkers in bot h serum, and urine specimens for secondary endpoints 
evaluation. Specifically, for miRNA signature, we w ill use protocols developed and validated by our 
group33 within the Cosmos 1 screening program.  
 
For serum hs-CRP and urine biomarkers (PGEM, leukotriene and cotinine) we will utilize standard 
protocols of commercially available kits already descr ibed in peer-reviewed publications. As to hs-CRP, 
our group has already published several papers involving this biomarker37,46-48. Two different methods 
have been applied. The former was a chemiluminescent enzyme immunometric assay (Diagnostic 
Products Corp, Los Angeles CA) designed  for the immulite automated analyzer. more recently a high 
sensitivity turbidimetric method for cobas integr a 800 was adopted (Roche Diagnostics, Mannheim, 
Germany). The two methods show ed an excellent correlation (r2=0.99).  
  10. SPECIMEN MANAGEMENT  
 
10.1 Laboratories 
 
The analysis of serum microRNA will be perfomed at the EIO laboratories of the Molecular Medicine 
Division (Chief Pierpaolo di Fiore) under the supervision of Fabrizio Bianchi, PhD. 
 
The analysis of serum ultrasensitive hs-CRP, and urin ary levels of cotinine, PGEM and LTE4 will be 
performed in the dedicated EIO lab of the Division of Lab Medicine under the supervision of Harriet 
Johansson, MSc, PhD. 
  
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –36– 
05/21/2013  10.2 Collection and Handling Procedures 
  
All blood and urine samples will be withdrawn under fasting condition (at least 6 hours) preferably 
between 8 a.m. and 10 a.m. at each time point. Instructions about sp ecimen handling and storage will be 
provided in a dedicated Manual of Procedures. 
 A total of 8 ml of blood will be withdrawn for safety labs (at baseline, 6 and 12 months) 
 A total of 4.5 ml  of blood will be collected for miRNA (at baseline and 12 months) with the following 
recommendation for each blood withdrawal: 
1) Patients should be fasting at least 6 hours before blood collection 
2) Information about oral therapy with anti-inflammato ry, anticoagulants, steroids or other drugs will be 
collected the same day. 
3) Patients must have been free of any infection (i ncluding flu) and inflammatory diseases for a week 
prior to the collection of blood samples. 
4) Before any instrumental or physi cal examination has been performed 
 
Fasting (at least 6 hours) blood samples will be collect ed in all participants free of any infection 
(including flu) and inflammatory diseases for a week prior to the collection of blood samples at baseline and after 12 months of treatment. In  order to avoid skin contamination, the first 3 mL of blood should not 
be used for serum preparation. Blood samples (4.5 ml) will be collected in tubes without anti-coagulant (white cap), left at room temperature for 30-60 minutes to clot, then spun at 3000 rpm (1000 g, Megafuge 2.0 – Heraeus) for 10 minutes at room temperature.  The serum will be immediately removed slowly by 
using a plastic transfer pipette, leaving 0.5 cm re maining to avoid disturbing the serum–clot interface, 
dispensed in 0.6 ml aliquots (for a total of 4 aliquots)  into 1.5 ml cryotubes (Thermo Fisher Scientific), 
specifically labeled with a barcode, and snap frozen in dry ice. Aliquots will then be transferred in a 
dedicated -80°C freezer. 
 A total of 7.5 ml  of blood will be collected into tubes containing clot activator for hs-CRP  (at baseline, 6 
and 12 months): Morning fasting blood samples are centrifuged at 1850xg and one ml serum  aliquots will be stored into 
1.5 ml cryotubes (Thermo Fisher Scientific), specif ically labeled with a barc ode and transferred in a 
dedicated -80°C freezer. 
 A total of 7.5 ml  of blood will be collected into tubes containing clot activator for TXB2  (at baseline, 6 
and 12 months): Morning fasting blood samples will be collected and the time of blood draw will be reported. Samples 
will be incubated at 25°-37°C (77-98.6°F) for 1 hour  and then centrifuged at 1000xg for 7 minutes. One 
ml serum aliquots will be stored into 1.5 ml cryot ubes (Thermo Fisher Scientific), specifically labeled 
with a barcode and transferred in a dedicated -80°C freezer.  First morning urine  samples (15 ml)  should be collected under fasting conditions following the standard 
procedure for appropriate urine collection (may be provided) and samples shoul d be kept refrigerated 
until arrival to hospital. Alternativ ely, samples should be collected unde r fasting conditions (15 ml) at the 
hospital in concomitance with blo od draw. Urinary creatine will be determined on fresh specimen to 
normalize subsequent urinary biomarker results. The re maining sample will be aliquoted into 2.0 ml 
cryotubes, specifically labeled with a barcode and transferred in a dedicated -80°C freezer. 
 A total 2.5 ml  whole blood will be collected at baseline and 12 months of treatment in tubes containing 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –37– 
05/21/2013  anti-coagulant CBC - Na-EDTA (red cap) and stored at -80°C in order to collect DNA and RNA for 
future unspecified analysis.  
DNA will be purified using the QIAamp DNA Blood Mini Kit (QIAGEN) that is designed for processing 
up to 200 μl fresh or frozen human whole blood with an expected yield of 4-12ug of DNA, which is 
sufficient for all downstream sequencing and PCR analyses. RNA will be purified using the QIAamp RNA Blood Mini Kit (QIAGEN) specifically designed for extracting high-quality RNA (1-5ug yeald) for all low- and high-throughput screening technologies (qRT-PCR, microarray, RNA-seq).  All DNA/RNA samples will be stored at -80°C in the IEO biobank (IBBRI).  
10.3 Shipping Instructions 
 
Samples will be collected and stored locally till shipping to EIO after study completion. Instructions about specimen handling and storage will be pr ovided in a dedicated Manual of Procedures. 
 
All samples will be shipped in compliance with the International Air Transport Association (IATA) 
Dangerous Goods Regulations. 
 
10.4 Tissue Banking 
 
Aliquots will be transferred in a dedicated -80°C freezer at the IBBRI and kept till measurement.  
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course 
of the study will be considered deliverables under the contract and thus the property of the NCI. At study 
completion, NCI reserves the option to either reta in or relinquish ownership of the unused biologic 
specimens. If NCI retains ownership of specimens, the Contractor shall collect, verify and transfer the 
requested biologic specimens from the site to a NCI-sp ecified repository or laboratory at NCI’s expense. 
 
 11. REPORTING ADVERSE EVENTS/ADVERSE DRUG REACTIONS 
 
DEFINITION ADVERSE EVENT (AE): AE means an y untoward medical occurrence associated with 
the use of a drug in humans, whether or not considered drug related. An AE can therefore be any 
unfavorable and unintended sign, symptom, or disease temporally associated with participation in a study, 
whether or not related to that participation. This incl udes all deaths that occur while a participant is on a 
study.  Please note that all abnormal clinical laboratory values that are determined to be of clinical significance 
based on a physician’s assessment are to be reported as AE s. Those labs determined to be of no clinical 
significance or of unknown clinical significance (per the physician’s assessment) should not be reported 
as AEs. Any lab value of unknown clinical significan ce should continue to be investigated/followed-up 
further for a final determination, if possible.  
A list of AEs that have occurred or might occur (Re ported Adverse Events and Potential Risks) can be 
found in §6.2, Pharmaceutical Information, as well as the Investigator Brochure or package insert.  
 
DEFINITION ADVERSE DRUG REACTION (ADR): all untoward and unintended responses to an 
investigational medical product related to any dose administered (Directive 2011/20/EC). 
 Comment: all AEs judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medical product qualify as ADR. Th e expression of reasonable causal relationship means 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –38– 
05/21/2013  to convey in general that there is evidence or argument to suggest a causal relationship (ENTR/CT/ 3 
April 2006).  
Unexpected ADR: an ADR, the nature and severity of wh ich is not consistent w ith the applicable product 
information (Directive 2001/20/EC-art. 2 §p; art 16§1)
 
 
11.1 Adverse Events 
 
11.1.1 Reportable AEs/ADRs 
 All AEs that occur after the informed consent is signed and baseline assessments are completed 
(including run-in) must be recorded on the AE CRC (paper and/or electronic) whether or not related to study agent. 
 
11.1.2 AE Data Elements:  The following data elements are required for adverse event reporting. 
 AE verbatim term 
 System Organ Class (SOC) 
 Common Terminology Criteria for Adve rse Events v4.0 (CTCAE) AE term 
 Event onset date and event ended date 
 Severity grade 
 Attribution to study agent (relatedness) 
 Whether or not the event was reported as a serious adverse event (SAE) 
 Whether or not the subject dropped due to the event 
 Outcome of the event 
 
11.1.3  Severity of AEs/ADRs    11.1.3.1  Identify the AE using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The CTCAE provides descriptiv e terminology and a grading scale for each adverse 
event listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopm ent/electronic_applications/ctc.htm  
 
AEs will be assessed according to th e CTCAE grade associated with the AE term. AEs that do not have a 
corresponding CTCAE term will be assessed according to  the general guidelines for grading used in the 
CTCAE v4.0. as stated below.  
 
CTCAE v4.0 general severity guidelines:  
 
Grade Severity Description  
1 Mild Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
2 Moderate Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL)*. 
3 Severe Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self-care ADL**. 
4 Life-threatening Life-threatening consequences; urgent intervention indicated. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –39– 
05/21/2013  5 Fatal Death related to AE. 
   
ADL  
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
 **Self-care ADL refers to bathing, dressing and undr essing, feeding self, using the toilet, taking 
medications, and not bedridden.  11.1.4 Assessment of relationship of AE/ADR to treatment   The possibility that the adverse event is related to st udy agent will be classified as one of the following: 
not related, unlikely, possible, probable, definite.   11.1.5 Follow-up of AEs/ADRs  All AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will 
be followed according to good medical practices and documented as such. 
 
11.2 Serious Adverse Events 
 
11.2.1 DEFINITION: According the European Direc tive 2001/20/EC and Fed. Reg. 75, Sept. 29, 2010 
defines SAEs as those events, occurring at any do se, which meet any of the following criteria: 
 Results in death 
 Is life threatening ( Note: the term life-threatening refers to an event in which the patient was at 
risk of death at the time of the event; it does not ref er to an event which hypothetically might have caused 
death if it were more severe).  
 Requires inpatient hospitalization or pr olongation of existing hospitalization 
 Results in persistent or significant incapacity or  substantial disruption of the ability to conduct 
normal life functions 
 Is a congenital abnormality/birth defect 
 Important medical events that may not result in death, be life-threatening or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they may 
jeopardize the patient or subject and may require medi cal or surgical intervention to prevent one of the 
outcomes listed. 
 
11.2.2 Reporting Serious Adverse Events 
The Sponsor is responsible for AE/ADR reporting to Regulatory Authority and Ethic Committee 
according to local regulation. The Principal Investigator will notify the Sponsor of any SAE within 24 hours of knowledge of the event. 
All SAEs (irrespective of suspected causation) which occur while the patient is on study must be reported 
by the investigator to the local ethics committee regul atory office and to Servizio Farmacia - European 
Institute of Oncology (fax: 0257489361) 
All relevant information about ser ious, unexpected adverse events su spected to be related to the 
investigational product that are fatal or life-threatening must be reported by the Sponsor to the Health Authority as soon as possible and in any case no later th an seven days after knowledge of such a case. 
Relevant follow-up information for these cases will be subsequentely submitted within an additional eight days. All other serious unexpected events suspected to be related to the investigational product must be reported as soon as possible, but within a maximum of 15 days of first knowledge by investigator. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –40– 
05/21/2013   
The organization that experiences the serious adverse event (SAE) should report the SAE to the following 3 entities: 1) NCI DCP, 2) DCP’s regulatory contractor CCSA, and 3) MDACC, the CLO.  Detailed 
reporting instructions are provided below.   
 11.2.2.1  The Lead Organization and all Participating Or ganizations will report SAEs on the DCP SAE 
form found at http://prevention.cancer.gov/sites/default/files/uploads/clinical_trial/SAE-form.pdf .  
 
11.2.2.2   Reporting within 24 hours of knowledge of the event.  
 
11.2.2.2(A) Report to the NCI DCP Medical Monitor within 24 hours:  
Contact the DCP Medical Monitor by phone within 24 hours of knowledge of the event.    Eva Szabo, MD 
NCI/Division of Cancer Prevention 
9609 Medical Center Drive, Rm 5E-102 Bethesda, MD 20892 (For FEdEX, Rockville, MD 20850) Phone: (240) 276-7011 Fax: (240) 276-7848 
Email: szaboe@mail.nih.gov 
 
 
Include the following information when calling the Medical Monitor: 
 Date and time of the SAE 
 Date and time of the SAE report 
 Name of reporter 
 Call back phone number 
 Affiliation/Institution conducting the study 
 DCP protocol number 
 Title of protocol 
 Description of the SAE, including attribution to drug and expectedness 
 
 
11.2.2.2(B) Report to the Consortium Lead Organization (CLO) PI (Dr. Powel Brown) within 24 
hours of knowledge of the event:  
Report all SAEs to the Consortium Lead Organiza tion PI (Dr. Powel Brown) within 24 hours of 
knowledge of the event.  The same information repor ted to the DCP Medical Monitor should be provided 
to the CLO via email, phone or fax within 24 hours of knowledge of the event.   11.2.2.2(C) Report to the drug supplier (Bayer) within 24 hours of knowledge of the event: Report all SAEs to Bayer (Fax: +49 30 468 967 65, email: GPV.CaseProcessing@bayerhealthcare.com) 
within 24 hours of knowledge of the event. The same  information reported to the DCP Medical Monitor 
should be provided to Bayer via fax or email, within  24 hours of knowledge of the event (Fax: +49 30 468 
96765, email: GPV.CaseProcessing@bayerhealthcare.com).  
11.2.2.3   Reporting within 48 hours of knowledge of the event: 
 
11.2.2.3 (A) FAX or email the written SAE reports to the DCP Medical Monitor within 48 hours of 
learning of the event using the paper SAE form. The SAE forms should be obtained at 
http://prevention.cancer.gov/sites/default/files/uploads/clinical_trial/SAE-form.pdf .  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –41– 
05/21/2013  11.2.2.3 (B) The written SAE reports will also be FAX’ed to DCP’s Regulatory Contractor, CCS 
Associates, at (650)691-4410 (phone:  (650)691-4400), email: safety@ccsainc.com 
 
11.2.2.3 (C) The written SAE report will also be faxe d or emailed to the Consortium Lead Organization 
PI (Dr. Powel Brown), at (713) 792-4003 or emailed to PHBrown@mdanderson.org .  
 
It is the responsibility of the CLO to inform the Lead Protocol PI upon receipt of the report from the organization experiencing the event.  
11.2.2.3 (D) The written SAE report will also be fa xed or emailed to Baye r Fax: +49 30 468 96765, 
email: GPV.CaseProcessing@bayerhealthcare.com 
 11.2.2.4  The DCP Medical Monitor and regulatory sta ff will determine which SAEs require FDA 
submission. 
 
11.2.2.5  The Lead Organization and all Participating Organizations will comply with applicable 
regulatory requirements related to reporting SAEs  to the local IRB/IEC, and to the DSMB.  
 11.2.2.6 Follow-up of SAE 
Site staff should send follow-up reports as requested when  additional information is  available.  Additional 
information should be entered on the DCP SAE form in  the appropriate format.  Follow-up information 
should be sent to DCP as soon as available. SAEs related to the study agent will be followed until 
resolved.  The Lead Organization and all Particip ating Organizations will comply with applicable 
regulatory requirements related to reporting SAEs  to the local IRB/IEC, and to the DSMB. 
  
12. STUDY MONITORING 
 
12.1 Data Management 
The study PI will identify a dedicated data manager who will be responsible for the correct management 
of the trial conduct. In particular, he/she will peri odically verify subject eligibility, informed consent 
signatures, accuracy and completeness of CRFs an d congruency with all s ource documents (including 
laboratory print outs, drug inventory and distructi on logs). All source documents will be collected in 
individual binders, stored in locked cupboards and acce ssible for any audit or inspection by authorized 
personnel. Should the PI change, custody of the records may be transferred to another competent person 
who will accept responsibility for those records. 
Written notice of such event has to be given to the local Ethics Committee at least one month in advance. 
This study will report clinical data using the Data  Management Initiative (DMI) web-based application 
managed by the Consortium Biostati stics and Data Management Core. Data Management Initiative (DMI) 
infrastructure has been developed in the Division of  Quantitative Sciences (DQS), MD Anderson Cancer 
Center. This infrastructure supplies integrated database and software services for web-based data 
collection, randomized treatment assignment, repo rting, query, data download, and data quality 
management. The DMI will be the database of record for the protocol and subject to NCI and FDA audit. All DMI users will be trained to use the DMI system  and will comply with the instructions in the 
protocol-specific “DMI User Manual” as well as appl icable regulatory requirements such as 21 CFR; Part 
11.  Data management procedures for this protocol ad heres to the Data Management Plan (DMP) contract 
HH2620100034I for Consortia 2012.  
12.2 Case Report Forms 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –42– 
05/21/2013  Participant data will be collected using protocol -specific case report forms (CRF) developed from the 
standard set of DCP Chemoprevention CRF Te mplates and utilizing NCI-approved Common Data 
Elements (CDEs). The approved CRFs will be used to  create the electronic CRF (e-CRF) screens in the 
DMI application. Site staff will enter data into the e-CRF. Amended CRFs will be submitted to the DCP 
Protocol Information Office for re view and approval.  Approved cha nges will be programmed into the 
DMI database by the Consortium Biostatistics and Data Management Core. 
 
12.3 Source Documents 
 
Source documentation will include only those documen ts containing original forms of data, including 
clinic charts, shadow files, hospital charts, and physician notes. Data recorded directly on the CRFs 
designated as source documents (i.e., no prior written or electronic record of data) will be considered 
source data. All other data recorded on the CRFs will not be considered source documentation. 
 
12.4 Data and Safety Monitoring Plan 
 
The Data and Safety Monitoring Plan for the MD Ande rson Consortium is on file at the DCP.  This study 
will be monitored by the MDACC Data and Safety Monitoring Board, the data and safety monitoring 
board of record for this study.   The Data Safety and Monitoring Board (DSMB) reports to the President, 
or his designee, as the on-campus representative of The University of Texas Board of Regents. It oversees 
the data and patient safety issues for randomized clini cal trials that originate at MD Anderson; that are 
coordinated or analyzed by MD Anderson and are not being monitored by any other DSMB; or have been 
designated as requiring DSMB monitoring at the request  of the IRB, the CRC, or institution. The primary 
objectives of the DSMB are to ensure that patients' rights pertaining to participation in a research study 
are protected, and that patients' interests are prioriti zed over the interests of the scientific investigation. 
Responsibilities include: 
(a) Review interim analyses of outcome data (prepared by the study statistician or other 
responsible person at the time points defined in the study) approved by the IRB and additional time points as determined by the DSMB, and to recommend, if necessary, whether 
the study needs to be changed or terminated based on these analyses; 
(b) Determine whether, and to whom, outcome resu lts should be released prior to the reporting of 
study results; 
(c) Review interim toxicity data and efficacy of treatment; 
(d) Review major research modifications proposed by the investigator or appropriate study 
committee prior to implementation (e.g., termin ation, dropping an arm based on toxicity 
results from the study or results of other studies, increasing target sample size). 
 
Refer to the Data and Safety Monitoring Plan for the MD Anderson Consortium on file at the DCP for 
further details. 
 
12.5 Sponsor or FDA Monitoring 
 
The Sponsor, members of the Ethics Committee, represen tatives of the Italian Ministry of Health or 
representatives of the national Competent Authority, the NCI, DCP (or their designee), pharmaceutical 
collaborator (or their designee), or FDA may monitor/audit various aspects of the study. These monitors 
will be given access to facilities, databases, supplies and records to review and verify data pertinent to the 
study.    
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –43– 
05/21/2013  12.6 Record Retention 
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study eligibility, history and physical findings, laboratory data, results of consultations, etc.), as well as 
IRB records and other regulatory documentation will be retained by the Investigator in a secure storage 
facility in compliance with Health Insurance Portability and Accountability Act (HIPAA), Office of Human Research Protections (OHRP), Food and Drug Administration (FDA) regulations and guidances, 
and NCI/DCP requirements, unless the standard at the site is more stringent. The records for all studies performed under an IND will be maintained, at a mi nimum, for two years after the approval of a New 
Drug Application (NDA). For NCI/DCP, records will be retained for at least three years after the 
completion of the research. NCI will be notified prior to the planned destruction of any materials. The 
records should be accessible for inspection and copyin g by authorized persons of the Food and Drug 
Administration. If the study is done outside of the United States, applicable regulatory requirements for 
the specific country participating in the study also apply. 
 
12.7 Cooperative Research and Developmen t Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  
 The agent(s) supplied by DCP, NCI, used in th is protocol, is/are provided to the NCI under a 
Collaborative Agreement (CRADA, CTA) between th e Pharmaceutical Company(ies) (hereinafter 
referred to as Collaborator(s)) and the NCI Division of Cancer Prevention. Therefore, the following 
obligations/guidelines, in addition to the provisions in the “Intellectual Property Option to Collaborator@ 
contained within the terms of award, apply to the use of Agent(s) in this study: 
 
12.7.1 Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be transferred or licensed to any party not participa ting in the clinical study. Collaborator(s) data for 
Agent(s) are confidential and proprietary to Collabor ator(s) and shall be maintained as such by the 
investigators. The protocol documents for studies utilizing investigational agen ts contain confidential 
information and should not be shared or distributed  without the permission of the NCI. If a patient 
participating on the study or participant’s family memb er requests a copy of this protocol, the individual 
should sign a confidentiality agreement. A suitable model agreement can be downloaded from the DCP 
website.  
12.7.2 For a clinical protocol where there is an Investigational Agent used in combination with (an) 
other investigational Agent(s), each the subject of different collaborative agreements, the access to and 
use of data by each Collaborator shall be as follo ws (data pertaining to such combination use shall 
hereinafter be referred to as "Multi-party Data”).  
12.7.3 NCI must provide all Collaborators with prior written notice regarding the existence and nature of 
any agreements governing their collaboration with NIH, the design of the proposed combination protocol, and the existence of any obligations that would te nd to restrict NCI's participation in the proposed 
combination protocol.  12.7.4 Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial by any 
other Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain 
regulatory approval, or commercialize its own investigational agent.  12.7.5 Any Collaborator having the right to use the Multi-Party Data from these trials must agree in 
writing prior to the commencement of the trials that it will use the Multi-Party Data solely for 
development, regulatory approval, and commercia lization of its own investigational agent. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –44– 
05/21/2013   
12.7.6 Clinical Trial Data and Results and Raw Da ta developed under a collaborative agreement will be 
made available exclusively to Collaborator(s), the NCI, and the FDA, as appropriate. All data made 
available will comply with HIPAA regulations.  12.7.7 When a Collaborator wishes to initiate a data re quest, the request should first be sent to the NCI, 
who will then notify the appropriate investigat ors of Collaborator's wish to contact them. 
 12.7.8 Any manuscripts reporting the r esults of this clinical trial must be provided to DCP for immediate 
delivery to Collaborator(s) for advisory review and comment prior to submission for publication. Collaborator(s) will have 30 days (or as specified in the CTA) from the date of receipt for review. Collaborator shall have the right to request that publi cation be delayed for up to an additional 30 days in 
order to ensure that Collaborator’s confidential a nd proprietary data, in add ition to Collaborator(s)’s 
intellectual property rights, are protected. Copies of abstracts must be provided to DCP for forwarding to 
Collaborator(s) for courtesy review as soon as possible and preferably at least three days prior to 
submission, but in any case, prior to presentation at the meeting or publication in the proceedings. Press releases and other media presentations must also be forwarded to DCP prior to release. Copies of any manuscript, abstract, and/or press release/ media presentation should be sent to:  
 Head, DCP Protocol Information Office 
 9609 Medical Center Drive, Room 5E450  Rockville, MD  20850  E-mail: NCI_DCP_PIO@mail.nih.gov  
 The Protocol Information Office will forward ma nuscripts to the DCP Task Order Monitor for 
distribution to the Collaborator(s). No publication, ma nuscript or other form of public disclosure shall 
contain any of Collaborator’s confidential/proprietary information.  Participant data will be collected using protocol-s pecific case report forms (CRFs) developed from the 
standard set of DCP Chemoprevention CRF Te mplates and utilizing NCI-approved Common Data 
Elements (CDEs).   
13. STATISTICAL CONSIDERATIONS 
 
13.1 Study Design/Description 
 
The trial will be a randomized double-blind place bo controlled phase IIb study. Patients will be 
randomized to receive either aspirin 100 mg/day or matched placebo for 1 year. Analysis will be 
performed according to intention to treat  principle and then according to efficacy. 
 
The primary endpoint will be the difference of the su m of longest diameters of subsolid (non-solid or 
partially solid) lung nodules in a person-specific analysis.  
 The sample size has been calculated assuming a -0.2  mm average reduction of the sum of the longest 
diameter of all non-solid and partially-solid lesions at 12 months with respect to baseline in the placebo 
arm vs. an expected average reduction of -1.0 mm in the aspirin group. 
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –45– 
05/21/2013  13.2 Randomization/Stratification 
 
In order to keep at minimum the imbalance in treat ments a stratified blocked randomization strategy will 
be used considering only the relevant prognostic fact ors. Subjects will be stratified according to screening 
vs non screening CT scan, gender, sm oking habits (current versus fo rmer smokers) and nodule type (non 
solid versus partially solid nodules). A blocked randomization will be done within each stratum. 
Other possible prognostic factors are age, the number of lesions, their volume doubling time and their size 
but since there is no evidence that they affect the response probability they will be included just in a 
stratified analysis, not during the randomization process.   
Justification of stratification:  
Stratification by nodule type and smoking status is planned because both non solid type and active 
smoking are associated with the risk of developing lung malignancies and their natural history, while stratification by screening vs non screening CT scan, a nd gender are conservative. The effect of aspirin 
has been variable in men and women for the prevention of certain conditions
49. 
 
13.3 Accrual and Feasibility 
 
A sample size of 128 patients (64 per arm) achieve 80% power to detect a difference of -0.8 mm between 
the null hypothesis that both groups average reductio n is –0.2 mm and the alternative hypothesis that the 
average reduction of target nodules in the aspirin group is –1.0 mm, with estimated effect size of 0.5 (common standard deviations of 1.6 mm) and with a significance level (alpha) of 0.05 using a two-sided 
two-sample t-test. The average shrinkage in the placebo arm is derived from the Budesonide trial. 
 
13.4 Primary Objective, Endpoint(s), Analysis Plan 
 
All randomized patients who received at least one dose will be included in the study analysis with an 
intent-to-treat approach. A secondary analysis will al so be carried out after excluding non-compliers and 
subjects who will drop-out and who will refuse treatment after randomization. 
Subject will be considered compliant if at least 80% of the drug has been taken. 
Using a more conservative approach, patients who dr op-out or have missing final CT scans will be 
considered in the failure group. Both the intent-to- treat and efficacy analyses will be conducted on a per 
subject basis A two-sided paired t-test will be used to compare the average cha nge in the dimension of 
sub-solid nodules in the aspirin gorup compared to the placebo group at 1 year.  
 
13.5 Secondary Objectives, Endpoints, Analysis Plans 
 
Generalized linear mixed models for longitudinal data will be used to compare the study groups using the 
standard general model y = X  + Zu + , with y  the response variable (e.g. secondary endopoint 
variable), X and  the design matrix and unknown parame ters for the fixed effects and Z the design 
matrix for the random effects and u the random effects. Treatment arm (aspirin or placebo) and time visit 
(baseline, 6 and 12 months) will be considered fixe d effects, smoking history and age at study entry 
random effects. Secondary endpoints include a per-lesion analysis by nodule type. Identity and logit link 
functions will be used for normal and binary data re spectively All tests will be two-sided and considered 
significant at the 5% level. 
 
13.6 Reporting and Exclusions 
 
Patients will be considered compliant with treatment if at least 80% of the drug has been taken. Non-
compliers and patients who switch the treatment assi gned will be excluded from the efficacy analysis. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –46– 
05/21/2013  Patterns of observations will be classified as co mplete cases (no missingness), terminal (monotone) 
dropouts, intermittent (non-monotone ) dropouts, mixed and no-data. A MCAR (Missing Completely At 
Random) vs. MAR (Missing At Random) statistical  test will be conducted as described by Little50. 
Kendall’s b will be computed in order to test the correlation between a dichotomous indicator of missing 
observations and treatment assigned as well as any possible baseline covariates. Multiple imputation 
procedures will be adopted only for those variable s whose missing data proportion will exceed the 5% 
value. 
 
13.7 Evaluation of Toxicity 
All participants will be evaluable for toxicity fr om the time of their first dose of Aspirin/placebo.  
 13.8 Evaluation of Response 
 
All participants included in the study who have taken at least one do se of study agent will be assessed for 
response to study treatment even if there are major protoc ol deviations or if they are ineligible. All of the 
participants who met the eligibilit y criteria (with the possible exception of those who did not receive 
study agent) will be included in the main analysis. All conclusions regarding efficacy will be based on all 
eligible participants. No subgroup analyses are foreseen.  
 
13.9 Interim Analysis 
 There is no interim analysis planned since repeat  CT is planned only at baseline and 1 year.  
 
13.10 Ancillary Studies 
 
None planned. 
  14. ETHICAL AND REGULATORY CONSIDERATIONS  
14.1 Form FDA 1572 
 Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s) 
will provide a signed Form FDA 1572 stating that th e study will be conducte d in compliance with 
regulations for clinical investigations and listing the inv estigators, at each site that will participate in the 
protocol. All personnel directly involved in the perfo rmance of procedures required by the protocol and 
the collection of data should be listed on Form FDA 1572. 
 
14.2 Other Required Documents 
 
14.2.1 Signed and dated current (within two years) CV or biosketch for all stud y personnel listed on the 
Form FDA 1572 and Delegation of Tasks form for the Lead Organization and all Participating 
Organizations.  
 14.2.2 Current medical licenses (where applicable ) for all study personnel listed on Form FDA 1572 and 
Delegation of Tasks form for the Lead Orga nization and all Participating Organizations. 
 14.2.3  Lab certification ( e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 
for the Lead Organization and a ll Participating Organizations. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –47– 
05/21/2013   
14.2.4  Documentation of training in “Protection of Human Research Subjects” for all study personnel 
listed on the FDA Form 1572 and Delegation of Ta sks form for the Lead Organization and all 
Participating Organizations.  14.2.5  Documentation of Federalwide Assurance (FWA ) number for the Lead Organization and all 
Participating Organizations.  14.2.6  Signed Investigator’s Brochure/Package Insert acknowledgement form 
 
14.2.7  Delegation of Tasks form for the Lead Organizati on and all Participating Organizations signed by 
the Principal Investigator for each site and initialed by all study personnel listed on the form  
 14.2.8  Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form 
FDA 1572 for the Lead Organization and all Participating Organizations 
 
14.3 Institutional Review Board Approval 
 
Prior to initiating the study and receiving agent, the Investigators at the Lead Organization and the Participating Organization(s) must obtain written appr oval to conduct the study from the appropriate IRB. 
Should changes to the study become necessary, prot ocol amendments will be submitted to the DCP PIO 
according to DCP Amendment Guidelines. The DCP-a pproved amended protocol must be approved by 
the IRB prior to implementation Locally, the study will be submitted for authorization and approval to the national competent authority 
and competent ethics committee in compliance with th e European and national regulations. All relevant 
communication as well as adverse event reporting to the regulatory authorities will be performed 
according to the national regulation. 
 
14.4 Informed Consent 
 
All potential study participants will be given a copy of the local IRB-approved Informed Consent to review. The investigator will explain all aspects of th e study in lay language and answer all questions 
regarding the study. If the participant decides to partic ipate in the study, he/she will be asked to sign and 
date the Informed Consent document.  The study agent(s) will not be released to a participant who has not 
signed the Informed Consent document. Subjects who refuse to participate or who withdraw from the study will be treated without prejudice.  Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues 
obtained during testing, operative pr ocedures, or other standard medical practices for further research 
purposes. Statement of this option may be included within the informed consent document or may be 
provided as an addendum to the consent.   Prior to study initiation, the informed consent document must be review ed and approved by NCI, DCP, 
the Consortium Lead Organization, and the IRB at each Organization at which the protocol will be 
implemented. Any subsequent cha nges to the informed consent must  be approved by NCI, DCP, the 
Consortium Lead Organization’s IRB, and then submitted to each organization’s IRB for approval prior to initiation.  
14.5 Submission of Regulatory Documents 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –48– 
05/21/2013  All regulatory documents are collected by the Cons ortium Lead Organization (CLO) and reviewed for 
completeness and accuracy. Once the CLO has recei ved complete and accurate documents from a 
participating organization, the CLO will forward the regulatory documents to the DCP Regulatory 
Contractor: 
  Paper Document/CD-ROM Submissions: 
 Regulatory Affairs Department  CCS Associates  1923 Landings Drive 
 Mountain View, CA 94043 
 Phone: 650-691-4400  Fax: 650-691-4410   E-mail Submissions: 
 regulatory@ccsainc.com  
 Regulatory documents that do not require an original signature may be sent electronically to the CLO for review, which will then be electronically forwarded to the DCP Regulatory Contractor.  
14.6 Other 
 This trial will be conducted in compliance with th e protocol, Good Clinical Practice (GCP), and the 
applicable regulatory requirements.  
 
15. FINANCING, EXPENSES, AND/OR INSURANCE 
 
Participants will not be responsible for the costs of this study. Study agent will be provided at no cost to 
the subject. If, as a result of participation in this study, an individual experiences injury from known or 
unknown risks of the research procedures as described in  the informed consent, immediate medical care 
and treatment, including hospitalization, if necessar y, will be available. Insurance coverage for 
participants is provided in accordance with all relevant legal requirements by the Sponsor (N. A1201436399 Sindacato Lloyd’s 1218 New Line).  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –49– 
05/21/2013  REFERENCES  
 
1. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: a study of 
incident cancers during randomised contro lled trials. Lancet 379:1591-1601, 2012 
2. Rothwell PM, Price JF, Fowkes FG, et al: Short-te rm effects of daily aspirin on cancer incidence, 
mortality, and non-vascular death: analysis of the ti me course of risks and benefits in 51 randomised 
controlled trials. Lancet 379:1602-1612, 2012 
3. Algra AM, Rothwell PM: Effects of regular aspirin on long-term cancer incidence and metastasis: a 
systematic comparison of evidence from observationa l studies versus randomised trials. Lancet Oncol 
13:518-527, 2012 
4. Rothwell PM, Fowkes FG, Belch JF, et al: Effect of  daily aspirin on long-term risk of death due to 
cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41, 2011 
5. Slatore CG, Au DH, Littman AJ, et al: Association of nonsteroidal anti-inflammatory drugs with lung 
cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 18:1203-1207, 2009 
6. Cook NR, Lee IM, Gaziano JM, et al: Low-dose aspirin in the primary prevention of cancer: the 
Women's Health Study: a randomized controlled trial. JAMA 294:47-55, 2005 7. Moysich KB, Menezes RJ, Ronsani A, et al: Regular aspirin use and lung cancer risk. BMC Cancer 
2:31, 2002 
8. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of aspirin to prevent colorectal adenomas in 
patients with previous colorectal cancer. N Engl J Med 348:883-890, 2003 9. Vane JR, Bakhle YS: Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharm acol Toxicol 38:97-120, 
1998 10. Xu XM, Sansores-Garcia L, Chen XM, et al: Suppression of inducible cyclooxygenase 2 gene 
transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 96:5292-5297, 1999 
11. Shiff SJ, Rigas B: The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal 
antiinflammatory drugs (NSAIDs). J Exp Med 190:4 45-450, 1999 
12. Dovizio M, Bruno A, Tacconelli S, et al: Mode of action of aspirin as a chemopreventive agent. 
Recent Results Cancer Res 191:39-65, 2013 
13. Sample D, Wargovich M, Fischer SM, et al: A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 11:275-279, 2002 
14. Ruffin MT, Krishnan K, Rock CL, et al: Suppressi on of human colorectal mucosal prostaglandins: 
determining the lowest effective aspirin dose. J Natl Cancer Inst 89:1152-1160, 1997 15. Barnes CJ, Hamby-Mason RL, Hardman WE, et al: Effect of aspirin on prostaglandin E2 formation 
and transforming growth factor alpha expression in human rectal muco sa from individuals with a history 
of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev 8:311-315, 1999 
16. Gorelick PB, Weisman SM: Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36:1801-
1807, 2005 
17. Lee M, Cryer B: Feldman M: Dose effects of aspirin on gastric prostaglandins and stomach mucosal 
injury. Ann Intern Med 120:184-189, 1994 
18. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N 
Engl J Med 348:891-899, 2003 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –50– 
05/21/2013  19. Weil J, Colin-Jones D, Langman M, et al: Prophylac tic aspirin and risk of peptic ulcer bleeding. BMJ 
310:827-830, 1995 
20. Henschke CI, McCauley DI, Yankelevitz DF, et al: Early Lung Cancer Ac tion Project: overall design 
and findings from baseline screening. Lancet 354:99-105, 1999 21. Veronesi G, Bellomi M, Mulshine JL, et al: Lung cancer screening with low-dose computed 
tomography: a non-invasive diagnostic protocol fo r baseline lung nodules. Lung Cancer 61:340-349, 
2008 22. Henschke CI, Yankelevitz DF, Libby DM, et al: Su rvival of patients with stage I lung cancer detected 
on CT screening. N Engl J Med 355:1763-1771, 2006 
23. Veronesi G, Maisonneuve P, Bellomi M, et al: Estimating overdiagnosis in low-dose computed 
tomography screening for lung cancer: a cohort study. Ann Intern Med 157:776-784, 2012 
24. Maisonneuve P, Bagnardi V, Bellomi M, et al : Lung cancer risk prediction to select smokers for 
screening CT--a model based on the Italian COSMOS tr ial. Cancer Prev Res (Phila) 4:1778-1789, 2011 
25. Henschke CI, Naidich DP, Yankelevitz DF, et al: Early lung cancer action project: initial findings on 
repeat screenings. Cancer 92:153-159, 2001 26. Kitami A, Kamio Y, Hayashi S, et al: One-dime nsional mean computed tomography value evaluation 
of ground-glass opacity on high-resolution imag es. Gen Thorac Cardiovasc Surg 60:425-430, 2012 
27. Kerr KM: Pulmonary preinvasive neoplasia. J Clin Pathol 54:257-271, 2001 28. Kim HY, Shim YM, Lee KS, et al: Persistent pulmonary nodular ground-glass opacity at thin-section 
CT: histopathologic comparisons. Radiology 245:267-275, 2007 29. Ohtsuka T, Watanabe K, Kaji M, et al: A clin icopathological study of resected pulmonary nodules 
with focal pure ground-glass opacity. Eur J Cardiothorac Surg 30:160-163, 2006 
30. Lee HJ, Goo JM, Lee CH, et al: Predictive CT findings of malignancy in ground-glass nodules on 
thin-section chest CT: the effects on radiologist performance. Eur Radiol 19:552-560, 2009 
31. Oda S, Awai K, Liu D, et al: Ground-glass opacities on thin-section helical CT: differentiation 
between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol 
190:1363-1368, 2008 
32. Veronesi G, Szabo E, Decensi A, et al: Random ized phase II trial of i nhaled budesonide versus 
placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 4:34-42, 
2011 
33. Bianchi F, Nicassio F, Marzi M, et al: A ser um circulating miRNA diagnostic test to identify 
asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3:495-503, 2011 
34. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002 
35. Gewurz H, Zhang XH: Lint TF: Structure and f unction of the pentraxins. Curr Opin Immunol 7:54-
64, 1995 36. Zhou B, Liu J, Wang ZM, et al: C-reactive protein,  interleukin 6 and lung cancer risk: a meta-analysis. 
PLoS ONE 7:e43075, 2012 37. Decensi A, Omodei U, Robertson C, et al: Eff ect of transdermal estradiol and oral conjugated 
estrogen on C-reactive protein in retinoid-placebo tr ial in healthy women. Circulation 106:1224-1228, 
2002 38. Boffetta P, Clark S, Shen M, et al: Serum cotinine level as predictor of  lung cancer risk. Cancer 
Epidemiol Biomarkers Prev 15:1184-1188, 2006 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –51– 
05/21/2013  39. Wall MA, Johnson J, Jacob P, et al: Cotinine in the serum, saliva, and urine of nonsmokers, passive 
smokers, and active smokers. Am J Public Health 78:699-701, 1988 
40. Wang D, DuBois RN: Eicosanoids and cancer. Nat Rev Cancer 10:181-193, 2010 
41. Duffield-Lillico AJ, Boyle JO, Zhou XK, et al: Le vels of prostaglandin E metabolite and leukotriene 
E(4) are increased in the urine of smokers: evid ence that celecoxib shunts arachidonic acid into the 5-
lipoxygenase pathway. Cancer Prev Res (Phila) 2:322-329, 2009 42. Zantek ND, Luepker RV, Duval S, et al: C onfirmation of Reported Aspirin Use in Community 
Studies: Utility of Serum Thromboxane B2 Measurement. Clin Appl Thromb Hemost , 2013 43. Yankelevitz DF, Reeves AP, Kostis WJ, et al: Small pulmonary nodules: volumetrically determined 
growth rates based on CT evalua tion. Radiology 217:251-256, 2000 
44. Therasse P, Arbuck SG, Eisenhauer EA, et al: New gui delines to evaluate the response to treatment in 
solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of 
the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000 
45. Kirschner MB, Kao SC, Edelman JJ, et al: Haem olysis during sample preparation alters microRNA 
content of plasma. PLoS ONE 6:e24145, 2011 46. Bonanni B, Puntoni M, Cazzaniga M, et al: Dual Effect of Metformin on Breast Cancer Proliferation 
in a Randomized Presurgical Trial. J Clin Oncol 30:2593-2600, 2012 
47. Decensi A, Gandini S, Serrano D, et al: Randomized dose-ranging trial of tamoxifen at low doses in 
hormone replacement therapy users. J Clin Oncol 25:4201-4209, 2007 
48. Decensi A, Robertson C, Viale G, et al: A ra ndomized trial of low-dose tamoxifen on breast cancer 
proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790, 2003 
49. Levin RI: The puzzle of aspirin and sex. N Engl J Med 352:1366-1368, 2005 50. Little RJA: A test for missing completely at ra ndom for multivariate data with missing values. J Am 
Stat Assoc 83:1198-1202, 1988 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –52– 
05/21/2013  Informed Consent Form 
 A RANDOMISED PHASE II TRIAL OF LOW DOSE ASPIRIN VERSUS PLACEBO IN HIGH RISK 
INDIVIDUALS WITH CT-DETECTED SUBSOLID LUNG NODULES 
 
(Testing aspirin in high risk lung cancer subjects with lung nodules) 
 This is a clinical trial, a type of research study. Y our study doctor will explain the clinical trial to you. 
Clinical trials include only people who choose to take  part in it. Please take your time to make your 
decision. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can  ask your study doctor for more explanation. 
You are being asked to take part in this study becau se you are at increased risk for lung cancer, you are 
already participating in a screening program in this Institute and/or you have a CT (Computer 
Tomography) scan recently performed having confirme d one or more small subsolid lung nodules.  
 What is the usual approach to my early detected lung nodules? 
 
Currently no effective drug to prevent lung cancer in people at increased risk has been discovered.  In 
your case these nodules are probably not cancerous but it is not possible to exclude that they may become 
cancers, so they should be monitore d with periodic exams to evaluate their growth rate. At the moment 
the growth of your nodules does not have clinical re levance, but requires a yearly follow up with a CT 
scan.  What are my other choices if I do not take part in this study?   If you decide not to take part in this st udy, you have other choices. For example: 
you may choose to have the usual appr oach described above, annual CT scan 
or you may choose to do nothing. 
 
Why is this study being done? 
 The purpose of this randomized phase II study is to compare the safety and effects of low dose aspirin 
(100 mg/day) with placebo on subjects with subsolid nod ules. In this study, you will get either aspirin 
100mg/day or placebo, a pill  that looks like the study drug but cont ains no medication. There will be 128 
subjects taking part in this study. The study will be conducted at the European Institute of Oncology in 
Milan, Italy and at the University of Texas MD  Anderson Cancer Center in Houston, TX, US.  
 
What are the study groups? 
 This study will enroll current and former asymptoma tic smokers, enrolled in lung cancer annual screening 
with low dose CT or having a confirming CT scan, presenting no clinically relevant nodules. The study population will be divided in two study groups. Group 1 will receive the study drug, aspirin 
100 mg/day, Group 2 will receive a placebo, a pill  that looks like the study drug but contains no 
medication.   A computer will randomly put you in a study group— like a coin toss—to decide what group you get 
placed into. This is done because no one knows if one st udy group is better, the same, or worse than the 
other group. Once you are put in a group, you cannot switch to the other group. Neither you nor your 
doctor will know if you are receiving the study drug  or placebo. Your doctor cannot choose which group 
you will be in.  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –53– 
05/21/2013   
   
 
 
 
 
How long will I be in this study? 
 
You will receive the study drugs for 12 months. Even if you do not finish the study, your doctor will continue to watch you for side effects and follow your  condition for 1 month after the discontinuation of 
the study drug. 
 
What extra tests and procedures will I have if I take part in this study? 
 At the moment the presence of pulmonary nodules requires only a yearly follow up with CT scan. 
However, there are some extra exams that you will need to have if you take part in this study (e.g., fasting 
state (at least 6 hours) for blood and urine exam, including serum pregnancy test in women of childbearing potential).  
 
Before you begin the study  
 
You will need to have the following extra tests and procedures to verify your eligibility (to find out if you 
can be in the study):  
Signed informed consent. Collection of fasting blood sample (about 30 ml) for safety routine tests and biological markers and urine sample for biological markers, including thromboxane B2 (TXB2), an indicator of aspirin use. Physical exam and record of any other medication that you are taking. 
If fully eligible you will be randomized to receive either aspirin or placebo and will be given a 7-month 
supply of aspirin or placebo.  The collection of these samples (blood and urine) is required in order for you to take part in this study because the research on the samples is an important part of the study.  
 
Month 1 (+/- 1 week from randomization) 
 
Through a telephone call, side effects and any other medication that you are taking will be recorded. 
 
Month 3 (+/-2 weeks from randomization) 
 
Through a telephone call, side effects and any other medication that you are taking will be recorded. 
Confirmation of Month 6 clinical visit.   
Month 6 (+/-2 weeks from randomization) 
 Collection of fasting blood (about 28 ml) and urine sample for safety routine tests and biological markers including TXB2, an indicator of aspirin use. Physical exam, record of any side effects and of any other medication that you are taking. You agree to take 
part in the study  Randomize           
(The computer will 
randomly put you      
in a study group) Group 1 
Aspirin 100 mg/day 
Group 2 
Placebo 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –54– 
05/21/2013  All the unused tablets will be returned. 
A 7-month supply of the study drug will be given.  
Month 9 (+/-2 weeks from randomization) 
 Through a telephone call, side effects and any other medication that you are taking will be recorded. 
Confirmation of Month 12 clinical visit.  
Month 12 (+/-2 weeks from randomization) 
 
Collection of fasting blood (about 30 ml) and urine sample for safety routine tests and biological markers 
including TXB2, an indicator of aspirin use. Physical exam, record of any side effects and of any other medication that you are taking. All the unused tablets will be return ed together with the calendar. 
 As part of the usual approach for your cond ition at month 12 you will have the annual CT scan . 
 
Month 13 (+/-1 week from Month 12) 
 Through a telephone call, the side effects and the concomitant medications will be recorded.  The most common risks of all these procedures are related to drawing blood from your arm: a brief pain 
and possibly a bruise.  
 
After Month 13 your participation to the aspirin study will be completed. You will continue the CT 
scan evaluation as needed. 
 What possible risks can I expect from taking part in this study?   
If you choose to take part in this study, there is a risk that you may:  
Lose time at work or home and spend more time  in the hospital or doctor’s office than usual. 
Be asked sensitive or private questions which you norm ally do not discuss. There is a risk someone could 
get access to the personal information in your medical records or other information researchers have kept 
about you. Someone might be able to trace this information back to you. The researchers believe the chance that someone will identify you is very small, but  the risk may change in the future as people come 
up with new ways of tracing information. In some cases, this information could be used to make it harder for you to get or keep a job.  There can also be a risk in finding out new genetic  information about you. New health information about 
inherited traits that might affect you or your blood relatives could be found during a study. 
There is also a risk that you could have side effects.   Here are important points about side effects: The study doctors do not know who will  or will not have side effects. 
Some side effects may go away soon, some may last a long time, or some may never go away.  
Some side effects may be serious and may even result in death.   Here are important points about how you and the study  doctor can make side effects less of a problem: 
Tell the study doctor if you notice or feel anything diff erent so they can see if you are having a side effect. 
The study doctor may be able to treat some side effects. 
The study doctor may adjust the study dr ugs to try to reduce side effects. 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –55– 
05/21/2013   
The tables below show the most common side effects that we know about aspirin, some of which may be 
serious, most of them very rare. There might be ot her side effects that we do not yet know about. If 
important new side effects are found, th e study doctor will discuss these with you. 
 Possible Side Effects of Aspirin: 
 
POSSIBLE, SOME MAY BE SERIOUS 
Many adverse reactions due to aspirin ingest ion are dose-related. The frequency of some 
individual side effects has not been determined  
Fever 
Low body temperature Thirst Irregular or rapid heartbeat Low blood pressure 
Agitation 
Swelling of the brain Coma Confusion Dizziness 
Headache 
Bleeding in the brain Tiredness Seizures Dehydration Increased blood potassium level 
More acid than normal in the 
blood Low blood carbon dioxide  Heartburn Gastrointestinal bleeding Nausea Vomiting Temporary elevations of liver 
enzymes 
Hepatitis Reye’s syndrome (symptoms include rash, vomiting, and liver damage) 
Pain in stomach 
Impaired blood clotting Formation of small blood clots inside the blood vessels Decreased blood platelets Allergic reaction 
Swelling of the lips and eyes 
Asthma Blockage of the airways  Hives Damage of muscle tissue Low blood sugar level (in children) High blood sugar level 
Prolonged pregnancy and labor 
Stillbirths Lower birth weight infants Bleeding associated with child birth 
Abnormally deep or rapid 
breathing Abnormal buildup of fluid in the lungs Hearing loss Ringing in the ears 
Swelling of the kidneys 
Kidney disease or failure 
 
Females must be postmenopausal (i.e, at least 1 year passed after the last menstruation), surgically sterile, 
or using acceptable birth control measures as judged by the Investigator. (A fertile woman is defined as 
being of child-bearing potential, from first menstruati on to 1 year after last menstruation). Negative serum 
beta-HCG for women of childbearing potential will be required at baseline and during study. It is 
important you understand that you need to use birt h control while on this study. Check with your study 
doctor about what kind of birth control methods to use and how long to use them. Some methods might 
not be approved for use in this study. For more info rmation about risks and side effects, ask your study 
doctor.  What possible benefits can I expect from taking part in this study? 
 
This study may or may not help you because we do not know how the study drug will compare to the 
usual approach for your condition. This study may help us to learn things  that could help people in the 
future. You have 50% chance to take Aspirin.  Aspirin may be protective against lung cancer. 
 Can I stop taking part in this study? 
 Yes. You can decide to stop at any time. If you deci de to stop for any reason, it is important to let the 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –56– 
05/21/2013  study doctor know as soon as possible so you can stop safely. If you stop, you can decide whether or not 
to let the study doctor continue to provide your medi cal information to the organization running the study. 
 
The study doctor will tell you about any new information or changes in the study that could affect your 
health or your willingness to continue in the study. 
 The study doctor may take you out of the study: If your health changes.  If the study is no longer in your best interest. 
If new information becomes available. 
If you do not follow the study rules. If the study is stopped early for any r eason by the sponsor, IRB or FDA. 
 
What are my rights in this study?  
Taking part in this study is your choice. No matte r what decision you make, and even if your decision 
changes, there will be no penalty to you. You will not lose medical care or any legal rights. 
 
For questions about your rights while in this study, call the 
________________________(insert name of center) In stitutional Review Board at 
__________________(insert telephone number). (Note to Local Investigator: Contact 
information for patient representatives or othe r individuals at a local institution who are 
not on the IRB or research team but take calls regarding clinical trial questions can also be 
listed here.)    
 
 
What are the costs of taking part in this study?  The study drug will be supplied at no charge while you ta ke part in this study. The cost of study-specific 
exams and tests, and any other procedures will be paid for by the study. For the Italian site only  
Some costs associated with your car e may be considered standard of car e, and billed to the national health 
system.  
For US site(s) only 
Some costs associated with your car e may be considered standard of care, and will be billed to you or 
your insurance company. You will have to pay for an y costs (including deductibles and co-payments) not 
covered by your health insurer.  Before you decide to be in the study, you should check with your health 
plan or insurance company to find out exactly what they will pay for.  
 
What happens if I am injured or hurt because I took part in this study? 
 
If you feel you have been injured or hurt as a result of ta king part in the study, it is important that you tell 
the study 
doctor immediately. You will get medical treatment if you are injured or hurt as a result of 
taking part in this study.  
 
The study sponsors will not offer to pay for medical treatment for injury. Your insurance company 
may not be willing to pay for study-related inju ry. If you have no insurance coverage, you would 
be responsible for any costs.  Even though you are in a study, you keep all of your legal rights to receive 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –57– 
05/21/2013  payment for injury caused by medical errors. 
 
 Who will see my medical information?  
 
Your privacy is very important to us and we will make  every effort to protect it. Your information may be 
given out if required by law. However, we will do our best to make sure that any information that is 
released will not be able to identify you. Some of yo ur health information, and/or information about your 
specimen, from this study will be kept in a centr al database for research. Your name or contact 
information will not be put in the database. 
There are organizations that may inspect your records.  These organizations are required to make sure your 
information is kept private. Some of these organizations are: The study sponsor and any drug company supporting the study  The Institutional Review Board, IRB, is a group of people who review the research with the goal of 
protecting the people who take part in the study. 
The Food and Drug Administration and the National Cancer  Institute in the US, and similar organizations 
if other countries are involved in the study (i.e. MDACC) The Italian Ministero della Salute The National Cancer Institute will obtain informati on from this clinical trial under data collection 
authority Title 42 U.S.C. 285. 
 
Where can I get more information? 
 
For more information about this study, call your study doctor’s office ( insert Local 
Investigator’s contact information) .  
 
The National Cancer Institute will obtain informati on from this clinical trial under data collection 
authority Title 42 U.S.C. 285.  
 
You may visit the NCI website at http://cancer.gov/  for more information about studies or 
general information about cancer. You may also  call the NCI Cancer Information Service to 
get the same inform ation at: 1-800-4-CAN CER (1-800-422-6237). 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by US 
law. This website will not include information that can  identify you. At most, the website will include a 
summary of the results. You can search this website at any time. 
 
Who can answer my questions about this study? 
 
You can talk to the study doctor about any questions or concerns you have about this study or to report 
side effects or injuries. Contact the study doctor __________________ (insert name of study 
doctor[s])  at __________________ (insert telephone number).  
  
Additional study section 
 This section is about optional studies you can choose to take part in  
This part of the consent form is about optional studi es that you can choose to take part in. You will not 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –58– 
05/21/2013  get health benefits from any of these studies. The resear chers leading this optional study hope the results 
will help other people with cancer in the future. 
 
The results will not be added to your medical record s, and you or your study doctor may not know the 
results. 
 You will not be billed for these optional studies.   You can still take part in the main study even if you say ‘no’ to any or all of these studies. If you sign up 
for but cannot complete any of the studies for any re ason, you can still take part in the main study. 
 
 
Optional Sample Collections for Biobanking for Possible Future Studies  
 
Researchers are trying to learn more about cancer, and other health problems. Some of this research is 
done using samples from your blood and urine. Through these studies, researchers hope to find new ways 
to prevent, detect, treat, or cure health problems.   
Some of these studies may be about genes. Genes carry information about features that are found in you and in people who are related to you. Researchers are interested in the way that genes affect how your 
body responds to treatment.   
If you choose to take part, a sample of blood and urine will be collected on the scheduled day of the main 
study. The researchers ask your permission to store and use your samples and health information for 
medical research. Both DNA and RNA will be prepared and stored for future unspecified analyses for 
markers of whole genome RNA and DNA profiling. The research that may be done is unknown at this 
time. Storing samples for future studies is called “biobanking”  The Biobank is being r un by Istituto Europeo di 
Oncologia (IBBRI) and the section regarding this study  is supported by the National Cancer Institute. 
If you need information about the biological sampl es or results obtained from the research, you can 
contact the coordinator of IBBRI, Dr Giuseppina Bonizzi (email Giuseppina.bonizzi@ieo.it or phone: 
+390294375155) 
 
What is involved? 
If you agree to take part, here is what will happen next: Your sample and some related information may be stored in the Biobank, along with samples and 
information from other people who take part. Th e samples will be kept until they are used up. 
Qualified researchers can submit a request to use the materials stored in the Biobank. A research 
committee at the clinical trials organization, and/ or the National Cancer Institute, will review each 
request. There will also be an ethics review to ensure that the request is necessary and proper. Researchers 
will not be given your name or any other in formation that could directly identify you.  
Neither you nor your study doctor will be notified if/when research is conducted using your samples.  
Some of your genetic and health information may be pl aced in central databases that may be public, along 
with information from many other people. Informa tion that could directly identify you will not be 
included.  
 
What are the possible risks? 
 The most common risks related to drawing blood from  your arm are brief pain and possibly a bruise.  
 There is a risk that someone could get access to the personal information in your medical records or other 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –59– 
05/21/2013  information we have stored about you. 
There is a risk that someone could trace the information in a central database back to you. Even without your name or other identifiers, your genetic inform ation is unique to you. The researchers believe the 
chance that someone will identify you is very small, but  the risk may change in the future as people come 
up with new ways of tracing information.   4) There are laws against the misuse of genetic information, but they may not give full protection. New health information about inherited traits that might affect you or your blood relatives could be found 
during a study. The researchers believe the chance th ese things will happen is very small, but cannot 
promise that they will not occur.   
For US site(s) only 
A new Federal law, called the Genetic Informati on Nondiscrimination Act (GINA), generally makes it 
illegal for health insurance companies, group health plans, and most employers to discriminate against 
you based on your genetic information. This law ge nerally will protect you in the following ways  
Health insurance companies and group health plans ma y not request your genetic information that we get 
from this research.  
 Health insurance companies and group health plans may not use your genetic information when making 
decisions regarding your eligibility or premiums.          Employers with 15 or more employees may not use yo ur genetic information that we get from this 
research when making a decision to hire, promote, or fire you or when setting the terms of your employment. All health insurance companies and group health plans must follow this law by May 21, 2010. All employers with 15 or more employees must follow this law as of November 21, 2009. 
 
Be aware that this new Federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance.      
How will information about me be kept private?  
Your privacy is very important to the researchers and they will make every effort to protect it. Here are just a few of the steps they will take: When your sample(s) is sent to the researchers, no information identifying you (such as your name or social security number) will be sent. Samples will be identified by a unique study code only. The list that 
links the unique code to your name will be kept sep arate from your sample and health information. Any 
Biobank and related staff with access to the list must si gn an agreement to keep your identity confidential. 
Researchers to whom Istituto Europeo di Oncologia sends your sample and information will not know 
who you are. They must also sign an agreement th at they will not try to find out who you are. 
Information that identifies you will not be given to anyone, unless required by law. 
If research results are published, your name a nd other personal information will not be used. 
 
What are the possible benefits?  
You will not benefit from taking part but the researchers, using the samples from you and others, might make discoveries that could help people in the future.  
Are there any costs or payments?  
There are no costs to you or your insurance. You will not be paid for taking part. If any of the research leads to new tests, drugs, or other commercia l products, you will not share in any profits. 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –60– 
05/21/2013  What if I change my mind? 
If you decide you no longer want your samples to be used, you can call the study doctor, _________________,  (insert name of study doctor for main trial) at ________________________ (insert 
telephone number of study doctor for main trial) who will let the researchers know.  Then, any sample that 
remains in the bank will no longer be  used. Samples or related informa tion that have already been given 
to or used by researche rs will not be returned. 
 
 
What if I have more questions?  
If you have questions about the use of your sa mples for research, contact the study doctor, 
________________, (insert name of study doctor for main trial) , at _____________________ (insert 
telephone number of study doctor for main trial). 
  
Please circle your answer to show whether or not you would like to take part in each option: 
 
 
SAMPLES FOR FUTURE RESEARCH STUDIES: 
 My samples and related information may be kept in Biobanks for use in future health research. 
  YES  NO  I agree that my study doctor, or their representative, may contact me or my physician to see if I wish to participate in other research in the future.  
 YES  NO 
   My Signature Agreeing to Take Part in the Main Study 
 
I have read this consent form. I have discussed it with the study doctor and my questions have been answered. I will be given a signed copy of this form. I agree to take part in the main study and any additional studies I circled “YES”  
 
 Participant’s signature ________________________________ 
 
 Date of signature_____________________________________    
 
Signature of person(s) conducting the informed consent discussion  
 ___________________________________  
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –61– 
05/21/2013  Date of signature_____________________________________  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –62– 
05/21/2013    
APPENDIX A 
 
Performance Status Criteria 
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity. Fully active, able to 
carry on all pre-disease performance 
without restriction. 100 Normal, no complaints, no evidence of 
disease. 
90 Able to carry on normal activity; minor 
signs or symptoms of disease. 
1 Symptoms, but ambulatory. Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some signs 
or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the time. Ambulatory and 
capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours. 60 Requires occasional assistance, but is 
able to care for most of his/her needs. 
50 Requires considerable assistance and 
frequent medical care. 
3 In bed >50% of the time. Capable of only 
limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
assistance. 
30 Severely disabled, hospitalization 
indicated. Death not imminent. 
4 100% bedridden. Completely disabled. 
Cannot carry on any self-care. Totally confined to bed or chair. 20 Very sick, hospitalization indicated. 
Death not imminent. 
10 Moribund, fatal processes progressing 
rapidly. 
5 Dead. 0 Dead. 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –63– 
05/21/2013  APPENDIX B CLINIC DIARY/CALENDAR 
Patient ID: __________________  Initials: _____/_____  Semester ____ (specify 1st or 2nd) 
 
This calendar will be provided to you every six months in order to record the drug daily intake. Please do not forget 
to take 1 tablet a day, every day, after food.  
Should you forget to take the drug, do not take any extra dose during the following day. Should you experience any symptom during the study, please write it down in the space provided and should you need any medical assistance, do not hesitate to contact the Division of Cancer Prevention and Genetics (02-94372657) during working hours. 
Please do not trash any empty bottle and do not forget to br ing with you all the drug boxes (empty o full) together 
with the present calendar at the next clinic visit. 
 
Month: _____________________________ 
 
1 
 2  3  4  5 6 
 7 
8 
 9  10  11  12  13  14 
15  16  17  18  19  20  21  
22  23  24  25  26  27  28  
29  30  31      
 
Month:_____________________________ 
 
1  2  3  4  5 6 
 7 
8 
 9  10  11  12  13  14 
15  16  17  18  19  20  21  
22 
 23  24  25  26  27  28  
29  30  31      
 
Month:_____________________________ 
 
1  2  3  4  5 6 
 7 
8  9  10  11  12  13  14 
15  16  17  18  19  20  21  
22 
 23  24  25  26  27  28  
29 
 30  31      
 
Please fill also the back pageNotes: 
 
 
 
 
 
 
 
 
 
Notes: 
 
 
 
 
 
 
 
 
 
Notes: 
 
 
 
 
 
 
 
 
 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –64– 
05/21/2013  Month:_____________________________ 
 
1 
 2  3  4  5 6 
 7 
8  9  10  11  12  13  14 
15  16  17  18  19  20  21  
22 
 23  24  25  26  27  28  
29  30  31      
 
Month:_____________________________ 
 
1 
 2  3  4  5 6 
 7 
8  9  10  11  12  13  14 
15  16  17  18  19  20  21  
22  23  24  25  26  27  28  
29  30  31      
 
Month:_____________________________ 
 
1  2  3  4  5 6 
 7 
8  9  10  11  12  13  14 
15  16  17  18  19  20  21  
22  23  24  25  26  27  28  
29  30  31      
 
Month:_____________________________ 
 
1  2  3  4  5 6 
 7 
8 
 9  10  11  12  13  14 
15 
 16  17  18  19  20  21  
22  23  24  25  26  27  28  
29  30  31      
 
  Notes: 
 
 
 
 
 
 
 
 
 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
Notes: 
 
 
 
 
 
 
 
 
 
Participant signature: ____________________________________________ Date ____/____/_____ 
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –65– 
05/21/2013  APPENDIX C 
 
 
 
Diagnostic algorithm for subsequent years CT detected nodules (WP4-2-2) 
 
 New detected nodules will be treated according to  WP4-2-1 algorithm (not applicable to the 
MDA2013-01-01 trial) 
 
Solid or partially solid nodules in prog ression will be managed according to VDT: 
 
 Nodules 5-8 mm and VDT >600 days CT after 1 year   Nodules 5-8 mm and VDT 400-600 days CT after 6 months   Nodules 5-8 mm and VDT < 400days CT after 3 months 
 
 Nodules >8 mm and VDT >600 days CT after 6 months   Nodules ≥8 mm and VDT < 600 days CT after 3 months 
 Non solid nodules in progression either in dimension (longest diameter) or density 
  Nodules <8 mm: CT after 6 months  Nodules >8 mm: CT/PET +biopsy 
  
DCP Protocol Number MDA2013-01-01 
IEO 833/13F (IEO37) Protocol version 9, version date March 13, 2017                    Protocol Version 14, Amendment 7, Dated March 13, 2017  
DCP Protocol Template Version 8.3 –66– 
05/21/2013  APPENDIX D 
 
 
Definition of smoking status  
 
As per Italian guidelines for epidemiological surv eys, the definition of smoking status is below 
(http://www.epicentro.iss.it/passi/rapporto2011/IndicatoriFumo.asp ).  The definition below will be used 
by all sites participating in the protocol: 
 Non smoker: a person declaring having smoked less than 100 cigarettes in his/her life (5 packs of 20 
cig/each) and not being smoker at the time of survey  Smoker (as per WHO definition): a person declaring having smoked more than 100 cigarettes in his/her 
life (5 packs of 20 cig/each), currently smoker or having interrupted smoking in the last 6 months   Occasional smoker: A smoker declaring of not smoking every day 
 Daily smoker: A person declaring smoking at least 1 cigarette/day 
 Former smoker: A person declaring having smoked more th an 100 cigarettes in his/her life (5 packs of 20 
cig/each), currently non smoke r and having interrupted smoking more than 6 months ago 
 